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SUMMARY 
Rationale/ Background 
Tuberculosis and HIV 
Tuberculosis (TB) is a major contributor to the disease burden in developing countries 
resulting in deaths of approximately 2 million people a year. South Africa (SA) has one 
of the highest annual TB incidences with an estimate of 558 per 100 000 population 
(2003) and the situation shows no sign of abating. TB remains the most common 
opportunistic infection and cause of death amongst HIV- infected patients. Both TB and 
HIV treatment depend exclusively on multi-drug regimens that require close monitoring 
among health care professionals.  
With increasing workload due to staff shortage and high patient load, the quality of care 
in nurse-led primary care clinics maybe compromised. Existing clinic staff may overlook 
drug-drug interactions, side effects and may not be aware of the consequences when a 
formulation is modified during multi-drug therapy administration.  
As the custodian of medicines, pharmacists are ideally placed to monitor therapy.  Clinic-
based training programmes which are offered to nurses provide an opportunity to work 
alongside clinic staff and engage in patient-centered care where the pharmacotherapeutic 
outcome of TB and HIV drug regimens could be closely monitored.  
Aims  
The primary and secondary aims of the study were to: 
• Assess current practice patterns of TB/HIV at primary healthcare clinics in the 
Western Cape, 
• Assess the need for a clinic-based TB/HIV training among final year pharmacy 
students in UWC. 
 
 
 
 
 
 
 xviii 
Objectives 
To achieve the primary aim the researcher; 
1. Conducted a baseline study at Ravensmead Community Health Centre(CHC) to 
assess current TB/HIV practice among HCP’s and co-infected patients, 
2. Assessed current practice patterns at Delft South ARV clinic and Elsies River TB 
clinic (pre-intervention), 
3. Designed and implemented a clinic-based TB/HIV intervention tool for potential use 
by pharmacists at Delft South and Elsies River clinics (intervention phase),  
4. Evaluated patient receptivity of the intervention tool amongst patients at Delft South 
and Elsies River clinics (post-intervention phase). 
To achieve the secondary aim the researcher; 
5. Introduced a clinic-based  training for seven final year pharmacy students,  
6. Designed and administered an assessment to both control and experimental students, 
7. Assessed scores between students who received the training (experimental) with those 
who did not receive the training (control). 
Results and discussion 
Findings from the baseline study indicate the need for involvement of a trained 
pharmacist in TB and HIV management. Even though three-quarters (77.8%; 14) of the 
patients preferred receiving their TB information from the clinic nurse, almost two-thirds 
(63.2%; 12) of the patients believed that pharmacists assisted with their treatment 
provision.  
 
Patient data obtained from the clinic record card showed that almost two-thirds of the 
patients reported that they had experienced side effects (64.4%); the therapy of more than 
one-quarter (26.4%) showed drug-drug interactions and onset of adverse effects (1.1%).  
Post-intervention, the data showed that patients’ viewed the pharmacist’s role more 
positively. Almost all responses (97.5%; 39) favoured the services of a pharmacist in the 
 
 
 
 
 xix 
clinic. In conclusion, findings from the post-intervention patient study clearly underpin 
that a clinic-based role for the pharmacist is imminent.  
 
All seven (100%) of the experimental students passed the assessment and had marks in 
the range between 26 and 45 and more than three-quarters (78.4 %; 29) of the control 
students passed with marks within this range.  
Conclusion 
A trained pharmacist would be competent to work alongside nursing staff in optimizing 
care provision in the clinical management of TB and HIV in patients. The existing clinic-
based TB/HIV programme could be supplemented with theoretical concepts in the final 
year of undergraduate pharmacy training. 
 
Keywords: Assessment, Current practice patterns, Tuberculosis, Human 
Immunodeficiency Syndrome, Primary Healthcare, Clinic-based training, Pharmacy 
students. 
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CHAPTER 1: INTRODUCTION  
 
1.1. Overview of Tuberculosis (TB) and HIV 
Tuberculosis 
Tuberculosis (TB) is caused by the organism known as M.tuberculosis and also to a 
lesser extent M.bovis and M.africanum. Tuberculosis (TB) is a major contributor to the 
disease burden in developing countries and remains a global challenge to the health 
services, resulting in deaths of approximately 2 million people a year. It is estimated that 
95% of all cases and 98% of all deaths occur in SA 
 
(Waisbord S, 2005). SA has one of 
the highest annual TB incidences with an estimate of 558 per 100 000 population 
(Internet Department of Health, 2006), and the situation shows no sign of abating even 
with the relatively good health care infrastructure and TB control activities. This is a 
disease whose morbidity and mortality rates continues to rise and has even been declared 
as a global emergency by the World Health Assembly, but still is poorly managed in SA 
(Department of Health, 1996).  
HIV 
The Joint United Nations programme on HIV/AIDS (UNAIDS) estimated that 40 million 
people were infected with HIV worldwide (2004). More than 95% of these people live in 
low and middle income countries and approximately 70% of them live in sub-Saharan 
Africa (Mansoor L.E, and Dowse R., 2006). Currently, it is estimated that 4.8 million 
South Africans are infected with HIV/AIDS every month, and an alarming 600 people die 
every single day (UNAIDS, 2004).  
 
Co- morbidities that exist between TB and HIV/ AIDS cannot be overlooked, because the 
incidence of TB has increased in parallel to the human immunodeficiency virus (HIV) 
epidemic(Bleed D et al, 2000; WHO, 2001). Tuberculosis remains the most common 
opportunistic infection and cause of death amongst HIV- infected patients (UNAIDS 
2000).  
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1.2. Rationale for this study 
Generally nurses manage only TB clinics. HIV clinics are commonly conducted by 
doctors. Some satellite HIV clinics are managed by nurses. These clinics involves stable 
patients.TB/HIV care is primarily managed by nurses. Their extensive administrative 
duties along with clinical responsibilities, attending to emergency care, monitoring 
treatment adherence and evaluating therapeutic outcomes could impact on the quality of 
care provision (Pillay R, 2009). In contrast, other healthcare professionals such as 
pharmacists are underutilized in the clinical management of TB and HIV. While they 
have a thorough knowledge of pharmacotherapy, they lack exposure to clinic-based 
management of TB/HIV. If a clinic-based training could be designed for potential use by 
pharmacists, it would strengthen the primary healthcare team approach to TB/HIV 
management. It is envisaged that such an intervention would improve the quality of care 
provision among HIV-positive patients.  
 
1.3. Hypothesis of this study 
The first hypothesis for this study is that co-infected patients who received an 
intervention (a trained researcher using a specially designed clinic-record card) will 
change their initial perceptions towards the pharmacists. The second hypothesis was that 
final year pharmacy students who received a clinic-based introductory session 
(experimental) will be able to apply theoretical concepts than those that did not receive 
the training (control). However, it was not possible to compare scores between the 
control and experimental students due to the difference in sample size attained during this 
phase of the study.  
 
1.4. Aims 
The primary aim of the study was to: 
• Assess current practice patterns of TB/HIV at primary healthcare clinics in the 
Western Cape and test the effectiveness of a clinic-based TB/HIV intervention, 
The secondary aim of the study was to: 
• Assess the need for a clinic-based TB/HIV training among final year pharmacy 
students in UWC. 
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1.5. Objectives 
 To achieve the primary aim the researcher; 
1. Conducted a baseline study at Ravensmead Community Health Centre (CHC) to 
assess current TB/HIV practice among HCP’s and co-infected patients, 
2. Assessed current practice patterns at Delft South ARV and Elsies River TB clinic 
(pre-intervention), 
3. Designed and implemented a clinic-based TB/HIV intervention tool for potential use 
by pharmacists at Delft South and Elsies River clinics (intervention phase),  
4. Evaluated patient receptivity of the intervention tool amongst patients at Delft South 
and Elsies River clinics (post-intervention phase). 
 To achieve the secondary aim the researcher; 
5. Introduced an introductory clinic-based session for seven final year pharmacy 
students,  
6. Designed and administered assessment to both control and experimental students, 
7. Assessed scores between students who received the training with those who did not 
receive the training. 
1.6. Brief description of research methods 
Quantitative and qualitative research methods were used throughout the different phases 
of this study. Qualitative research methods such as participant observation and interviews 
was used to generate rich, detailed data that is imbedded in context while quantitative 
methods such as the use of semi-structured questionnaires was used to convert the data 
into numbers which were then analyzed using the Epi Info 1993 package. Two sets of 
questionnaires were designed namely pre-intervention and post-intervention 
questionnaires. The intervention consisted of a trained researcher who used a clinic 
record specially adapted for potential use by pharmacists. The card was modified from 
the nurses TB clinic record card that is used routinely in TB/HIV clinics. 
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Patients were randomly selected from each clinic namely Delft South ARV and Elsies 
River TB clinics. The Solomon four-group design was used in this study and patients 
enrolled were assigned to either a control group or an experimental group. Patients 
assigned to the experimental group received the pre-intervention questionnaire, 
intervention and post-intervention questionnaire whilst the control group patients 
received only the pre-and post intervention questionnaires but they were not exposed to 
the intervention.  
1.7. Study Phases 
This study consisted of 2 phases namely: Phase I which entailed the baseline study, pre-
intervention, intervention and post-intervention studies with TB/HIV patients attending 
primary care clinics and Phase II consisted of final year pharmacy student’s assessment 
and an introductory clinic-based session. 
Phase 1 
The aim of the baseline study was to assess the current practice patterns of TB 
management provided to TB patients by nursing staff. The baseline study was conducted 
at Ravensmead Community Healthcare Centre (CHC). A face-to-face questionnaire 
directed to the patients, and HCP’s was designed and was used to collect data on routine 
TB care provision from the clinic. 
Following findings from the baseline study, the patient and HCP questionnaires were 
subsequently modified for their implementation at the intervention clinics. The 
intervention consisted of a trained researcher using a specially adapted clinic record card 
for the pharmacotherapeutic management of TB/HIV positive patients. The intervention 
took place over a period of 3 months at Delft South ARV clinic and 1 month at Elsies 
River TB clinic from July 2008-October 2008.   
The aim of the pre-intervention study was to assess patient perceptions towards the 
pharmacist and knowledge of their TB/HIV treatment. Data was collected from 
questionnaires used during semi-structured interviews that lasted for approximately 10 
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minutes per patient.  A total of 19 co-infected patients received the pre-intervention 
questionnaires.  
The aim of the intervention study was to assess the effect of the pharmacotherapeutic 
intervention used on patients receiving TB/HIV treatment. The trained researcher used 
the intervention tool for 4 months (July to October, 2008) to collect clinical data. A total 
of 98 co-infected patients from Delft South ARV clinic and Elsies River TB clinic 
received the intervention. 
 
The aim of the post-intervention study was to assess patient receptivity and effect of 
intervention on the quality of care provision. Data was collected from 48 patients that had 
previously received the intervention (trained researcher using specially designed clinic 
record card) by using questionnaires. 
 
Phase 2 
The aim was to assess final year pharmacy students’ on their current TB/HIV knowledge 
and assessment scores of students who received an introductory clinic-based TB/HIV 
session and those who did not. The researcher designed an assessment and this was used 
as the sole method of data collection from both the control and experimental students.  
 
1.8. Chapter description 
Chapter 2- provides a comprehensive literature review of TB and HIV as co-morbid 
conditions. This chapter is subdivided into two sections namely section A and B. Section 
A reviews both quantitative and qualitative literature whilst section B provides the 
rationale for TB/HIV training for final year UWC pharmacy students.  
 
Chapter 3- provides an overview of the research methods applied during the different 
phases of this study. It concludes with a schematic representation of the qualitative and 
quantitative methods used in different phases of this study. 
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Chapter 4- describes the clinic-based PALSA Plus training that the researcher received. 
This training equipped the researcher with the clinic insight and procedures required in 
the management of TB and HIV. This chapter discusses the results obtained during the 
baseline study conducted at Ravensmead Community Health Centre.  
 
Chapter 5- describes the design and implementation of the intervention tool (clinic 
record card) at Delft South ARV and Elsies River TB clinics. It concludes with an outline 
of the clinic-based TB/HIV training conducted by the researcher to the final year 
pharmacy students.  
 
Chapter 6- provides the results of the pre-intervention, intervention and post-
intervention phases. The quantitative results are expressed as numbers and where 
applicable tabulated whilst the qualitative data were complied from observations, 
interviews and semi-structured questionnaires.   
 
Chapter 7- this chapter discusses the implication of findings from the preintervention, 
intervention and post-intervention phases to the patients, HCPs and final year pharmacy 
students.  
 
Note: In this thesis, as a participant observer I mimicked the role of a trained 
pharmacist, where I engaged with clinic staff and patients to explore a clinic-based 
TB/HIV intervention.  
 
Use of personal pronoun 
In this thesis, the terms researcher and “I” will be used interchangeably. 
Use of numbers 
In this thesis, numbers less than ten are written in words and those greater than ten are 
written in numbers. 
Referencing 
The bibliography follows the Harvard style of referencing. Referencing is by first author 
(where available) and year of publication in parenthesis in the text. 
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CHAPTER 2: LITERATURE REVIEW 
 
This chapter is divided into two sections namely section A and B. Section A reviews the  
epidemiology of  TB and HIV, transmission of TB, prevalence and incidence rates for 
TB, the burden of co-infection, and the treatment challenges in children with TB. I 
review the South African health system including primary healthcare in the Western 
Cape, and discuss the barriers that are encountered in practice. I outline the clinical 
management of TB/HIV, drug strategies used to improve adherence and ART initiation in 
patients with TB. Finally, I discuss the views of other healthcare professionals in TB/HIV 
management. Section B assesses the current status of undergraduate (final year) 
pharmacotherapeutic training in TB/HIV management.     
 
Section A 
2. TB and HIV: Epidemiology 
It is estimated that about one third (2 billion) of the world’s total population has latent 
tuberculosis, caused by the pathogen belonging to the M. tuberculosis complex, primarily 
M. tuberculosis (Koch’s bacillus), and rarely Mycobacterium bovis or M. africanum 
(Raviglione MC et al, 1995; Aaron L et al, 2004). From the world’s population, 8-9 
million cases of active TB emerge annually, resulting in 2-3 million deaths (Snider et al, 
1994). The highest incidence rate is seen in sub-Saharan Africa, the Indonesian and 
Philippine archipelagos, Afghanistan, Bolivia, and Peru (Chan ED, and Iseman MD, 
2002). Thus TB remains the single biggest killer in developing countries (UNAIDS 
2002). Globally, the HIV and TB epidemics are stroking each other, creating a public 
health crisis of enormous proportions. It was estimated that at least 10.7 million persons 
were co-infected with HIV and TB (1997), and that HIV-1 patients represent 8% of the 
worldwide total of TB cases (Dye C et al, 1999). Because of the infectious nature of TB, 
it remains an ongoing public health concern.  
 
The Joint United Nations Programme on HIV/AIDS (UNAIDS), estimated that out of the 
42 million people living with HIV/AIDS globally, 70% (29.4 million) were in sub-
Saharan Africa. Twenty-three sub-Saharan African countries had an adult HIV 
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seroprevelance rate (1999) greater than 5%, superceeded only by Haiti. Eight of these 
twenty-three countries (all in Southern Africa), showed that the adult HIV seroprevelance 
rate was above 15% and that sub-Saharan Africa bears most of the overwhelming burden 
of the HIV/AIDS epidemic (UNAIDS, 2002). 
Transmission of TB 
TB commonly affects the lungs but can cause disease in any part of the human body. It 
spreads by airborne route through inhalation of droplet nuclei and transmission can occur 
in several ways: 
• When a patient who is already infected has a productive cough for 2 weeks or   
more, 
• Living with someone infected with pulmonary TB in a place where there is no 
cross- ventilation, where windows are small or closed most of the time, or 
• The longer one stays with an infected person who coughs, the more likely one is 
to become infected with TB (National Department of Health, April, 2007).  
 
Clinical signs and symptoms of TB include; chronic cough (≥ 2 weeks), weight loss, 
coughing up blood, chest pains, drenched night sweats, tiredness and weakness of the 
body, and loss of appetite. 
Transmission of HIV 
The main routes of HIV transmission vary between regions. The main routes of 
transmission of HIV in sub-Saharan Africa are through sexual intercourse, blood and 
from mothers to their infants. Blood borne HIV transmission occurs through 
contaminated blood transfusion, injections with contaminated needles and syringes, and 
the use of non-sterile skin-piercing instruments (Harris A et al, 2004).  
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2.1. Prevalence and incidence of TB 
In spite of  increasing knowledge and control measures (e.g. STOP TB strategy), there 
has been a resurgence of TB in many parts of the world,  a situation that led the World 
Health Assembly (1993) to take the extraordinary step of declaring TB a global 
emergency (Buso DL et al, 2000; Afari-KT et al, 2005). Although the incidence of TB 
has declined in developed countries (North America and Western Europe), detection rates 
in Southern Africa have increased mainly because of immigration, HIV/AIDS, and the 
neglect of tuberculosis control programmes (Cantwell MF et al, 1992; Burwen DR et al, 
1995). 
 
South Africa (SA) has one of the highest annual TB incidences in the world. SA reported 
302 457 cases of TB which translates to an incidence rate of 645 per 100 000 population 
in 2005 increasing to 342 315 in 2006 (National Department of Health, 2007-2011).  In 
2006, 27,017 TB clients were registered with an incidence of 867 per 100,000 population 
(City Health: TB in Cape Town). As the HIV epidemic in SA progresses, the incidence of 
new cases of TB continues to increase because an individual’s susceptibility to TB is 
increased from the time of HIV infection. SA is ranked among the top 5 of 15 countries 
with the highest estimated TB incidence rates per capita (all ages) and their 
corresponding incidence rates of HIV infected TB.  Graph 1 below shows the percentages 
(numbers above the bars) of Mycobacterium tuberculosis–HIV co-infection (Corbett EL 
et al, 2003). Therefore, concerted efforts from healthcare professionals are needed to 
manage patients who are diagnosed with these diseases. Regular monitoring and 
evaluation of treatment outcomes is cornerstone to care provision.  
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Graph 1: Fifteen countries with the highest estimated TB incidence rates per capita 
(all ages) and their corresponding incidence rates of HIV infected TB (Corbett EL et 
al, 2003). 
 
2.2. Burden of co-infection with TB and HIV 
 
Nelson Mandela on July 15, 2005 in a media briefing on ‘Confronting the joint HIV-TB 
Epidemics’ stated that ‘ The world has made defeating AIDS a top priority. This is a 
blessing. But TB remains ignored. Today we are calling on the world to recognize that 
we can’t fight AIDS unless we do much more to fight TB as well.’ 
TB is a major cause of morbidity and mortality worldwide and the situation is worsened 
by the HIV pandemic (Pedro C et al, 2003; 106). TB is by far the most common 
opportunistic infection diagnosed during the first three months on ART — particularly in 
Africa. Two hundred thousand people with HIV die of TB each year, again, most of them 
in Africa (Smart T, 2007).   
Recent data from WHO/STOP TB Partnership shows that globally 14 million people are 
co-infected with TB and HIV but around 80% of those who are co-infected live in Sub-
Saharan Africa. In Sub-Saharan Africa, the incidence rates of TB increased from 146 per 
100 000 (1990) to 345 per 100 000 (2003) due to HIV (WHO report, 2005).  
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Five million of the 40 million people infected with HIV worldwide are in SA, amounting 
to approximately 10% of the population (Benatar SR, 2004). TB remains the most 
common opportunistic infection and cause of morbidity and mortality in HIV-infected 
South Africans (Rowe KA et al, 2005). The emergence of multi-drug resistant TB 
(Medical Research Council, 2000) imposes an additional burden to the health system in 
resource-limited countries. The World Health Organization (WHO, 2005) stated that as a 
result of HIV, SA was ranked seventh out of 22 high burden TB countries (defined as 
countries that contribute 80% of the total global TB burden) and had the fifth highest 
number of notified TB cases in the world. In this same year, the annual incidence of TB 
was 536 per 100 000 with 61% of patients diagnosed as having both TB and HIV (WHO 
report, 2005; National Department of Health, 2007-2011).  
Changes in TB notification data from a Cape Town peri-urban township over the last 10 
years reported that HIV adult seroprevelance has increased from 8% (1996) to 23% 
(2005) indicating the impact of HIV on a TB clinics ( Lawn SD et al, 2006). During this 
period TB incidence rates increased 4.75-fold from 400 per 100 000 to 190 000 per 100 
000 (1999-2005), with the highest increase occurring in 20-40 age groups (Wood R, 
2007). 
 
An annual TB/HIV co-infection showed an incidence of 2.7%, with an estimate of 1.5% 
in males and 3.6% in females.  The prevalence of HIV was found to be 13.3% in females 
and 8.2% in males (HSRC, 2005). This statistic clearly shows that TB/HIV prevalence is 
higher in women than in men. Such an enormous disease burden underpins the need for 
collaborative efforts from healthcare professionals to explore management strategies to 
combat the growing epidemic. 
 
2.3. Children and TB: Challenges 
TB remains one of the major diseases afflicting children worldwide, with approximately 
1 million new cases and 400 000 deaths per year (WHO guidelines for national TB 
programs on the management of TB in children, 2006). ART in children follows the same 
principles as in adults. The main differences are that dosing is more complex, and 
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requires careful titrations. Dosing is often based on surface area, and liquid formulations 
require exact measurements. Since there are no fixed dose combinations suited for 
children yet, frequent re-adjustment of dosing is necessary. Liquid formulations are 
problematic in that they often have an unpleasant taste, and in some cases involve 
administration of large volumes of liquids. Dosing also involves the use of syringes for 
liquid formulations and it requires special attention by the caregiver when drawing the 
correct volume and expelling excess air (Southern African Journal of HIV Medicine, 
Antiretroviral therapy in children, 2005: 18-19). Children were excluded from this study 
because of the complexity involved in dosing and the level of specialized care required 
by well-trained healthcare professionals.  
2.4. The South African Healthcare system 
The South African healthcare system comprises of both private and public health sectors 
(Geyer SN et al, 2002). Although the state contributes about 40% of all expenditure on 
health, only 11% of the government’s budget is allocated for healthcare and the public 
health sector is therefore under pressure to deliver services to about 80% of the 
population. The healthcare delivery system of South Africa is based on a comprehensive 
primary healthcare approach with an expanded district-based system of care. Most health 
professionals work in private sector hospitals except for the majority of nurses who are 
employed in the public sector (Benatar SR, 2004; South Africa .info, 2007).  An added 
strain on the South African healthcare system is the continual loss of its trained doctors 
and nurses who are highly sought after in other countries (DOH, 2007; South Africa 
.info, 2007). Therefore public sector healthcare facilities are severely understaffed.  
2.4.1. Primary Healthcare in the Western Cape 
Primary healthcare (PHC) is the backbone of the South African healthcare system and 
local authority clinics (City Health) renders primary healthcare services through the 
district health system. PHC services rendered include amongst others: HIV/AIDS 
treatment, care programmes and TB control programmes.  
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In SA, TB is managed by nurses employed by Local Authority/ Municipal health clinics.  
Cape Town is a city of extremes with 86% of the population uninsured and reliant on 
public health services.  Even though the City of Cape Town’s eight health sub-districts 
boast the best rate of curing TB in SA, there are 25, 000 people in the city metro area that 
have TB. About two-thirds of these people are also living with HIV and AIDS. The city’s 
health directorate uses the World Health Organization’s DOTS method in its 93 clinics 
and they work closely with the TB Care Association and other non-governmental 
organizations to recruit and train TB treatment supporters. These supporters visit patients 
at home or observe them taking their treatment in the clinics. 
(www.capetown.gov.za/health: TB in Cape Town).  
 
2.4.2. Health services barrier to TB/HIV management 
The proposed ARV plan of the Department of Health requires 28 doctors to treat every 
10 000 patients. The public health system requires 1 400 additional doctors to handle the 
target of 500 000 patients on ARV, excluding other professionals such as pharmacists and 
nurses. Inadequate resources and the burden of the disease already challenge the 
healthcare system. Recruiting medical practioners is difficult; therefore it is vital that 
other healthcare professionals be collectively involved to make a substantive contribution 
to HIV/AIDS management (Department of Health, 2003; www.aidsmap.com, 2003). 
Integration of services may help overstrained health systems to cope with the 
unparalleled dual burdens of the TB and HIV epidemics.  
 
HCP’s and Patients: barriers 
A major barrier to accessing free government-provided antiretroviral treatment (ART) in 
SA is the shortage of suitably skilled health professionals. Despite efforts to improve 
quality of care for these patients, many fail to complete their treatment as prescribed. 
Poor rapport between health care providers and patients with TB is a major reason for 
non-adherence to treatment (Dick J et al, 2004). 
 
 
 
 
 
 14 
In SA, the shift in service delivery from inpatient services to outpatient services and from 
hospitals to clinics increases the workload in PHC services (Quinlan T, and Veenstra N, 
2007). Public-sector nurses are extremely overloaded and the emergence of deadly 
diseases such TB and HIV/AIDS  in the wake of the already burdened public health care 
system contributes further to their workload since patients with these illnesses generally 
require more specialized care and long-term treatment than other patients (Pillay R, 
2009). An increased workload among nurses resulting from the severe staff shortage as 
well as increased demand for care has led to burnout (Cameron SJ et al, 1994).   
2.5. Clinical management of TB/ HIV 
In SA management of TB is mainly done at the primary healthcare (PHC) level and 
nurses at the primary level manage approximately 90% of TB patients at clinics 
(Department of Health, 2000; Dick J et al, 2004). These clinics also arrange for people 
suffering from TB to receive treatment at their place of work away from the community. 
Nurses provide clinical services such as screening new suspects for TB, treating and 
tracing TB contacts, giving preventive treatment (BCG vaccine) to children who have 
been exposed to TB and providing social assessments.  
2.6. Approaches to TB drug treatment 
 
WHO and the International Union against Tuberculosis and Lung Disease (IUATLD) 
recommend the use of fixed-dose combinations for the treatment of TB. Fixed-dose 
combination tablets include two or more drugs within the same tablet. The use of four 
drug combinations for the treatment of TB includes rifampicin, isoniazid, ethambutol and 
pyrazinamide known as Rifafour®. The advantages of fixed drug combinations are as 
follows: 
 
• An increase in compliance as patients having fewer pills to swallow, thereby  
making treatment easier to take orally and it reduces the likelihood that people 
will split doses or only take some of the pills they have been given.  
• Reduction in the emergence of drug resistant-TB by ensuring that more than one 
drug is used and reducing the occurrence of incorrect drug selection. 
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2.6.1. Cotr imoxazole Prophylaxis Therapy (CPT) 
Co-trimoxazole is given routinely for the prevention of opportunistic infections in HIV-
infected patients. Co-trimoxazole is a fixed dose combination of Sulfamethoxazole and 
Trimethoprim. This combination is also referred to as Bactrim® and is a broad spectrum 
antibiotic that kills a range of gram-positive and gram-negative organisms, fungi, and 
protozoa. Co-trimoxazole is given to TB patients for the entire duration of their 
treatment.  
2.6.2. TB treatment regimens 
The National Tuberculosis Control Programme decides upon TB regimens in South 
Africa. These regimens are based on the characteristics and proven efficacy of the 
medicines, although regimens may deviate from this for special circumstances e.g. known 
resistance, pregnancy, treatment of children. 
 
Table 1.1: Commonly used abbreviations for TB drug treatment 
Isoniazid H INH 
Rifampicin R RIF 
Pyrazinamide Z PZA 
Ethambutol E EMB 
Streptomycin S SM 
 
2.6.3. Pharmacological properties of individual anti-TB drugs 
 
Isoniazid (INH)  
This drug is highly bactericidal and is given orally once a day. It is safe to use during 
pregnancy. It is more likely to cause hepatotoxicity than any other first-line anti-TB drug. 
Peripheral neuropathy can occur due to INH-induced Vitamin B6 (pyridoxine) deficiency 
especially in pregnant or undernourished patients, alcoholics, and the elderly. However, a 
daily dose of pyridoxine (25-50mg) can prevent this.  
 
Rifampicin (RIF)  
This drug is also bactericidal which is given orally and is well absorbed. It is used 
because it eliminates dormant organisms in macrophages that cause late relapse and is 
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given throughout therapy. It adds slightly to the hepatotoxicity of INH but is also safe 
during pregnancy. A common adverse effect is discoloration of urine and is a potent 
hepatic enzyme inducer.  
 
Pyrazinamide (PZA)  
It is bactericidal and is also given orally. It is given to prevent the development of 
resistance to RIF and shortens therapy to 6 months when used during the intensive initial 
2 months of treatment. Main adverse effects associated with PZA are gastrointestinal 
upset and hepatitis. This drug is contraindicated in pregnancy.  
 
Ethambutol (EMB)  
This drug is the best tolerated of all four anti-TB first line drugs. It is bactericidal and is 
also taken orally. Its main adverse effect is optic neuritis at high doses.  
 
Streptomycin (S)  
It is the most commonly used aminioglycoside and is also bactericidal. It is 
contraindicated in pregnancy because of damage to the 8th
 
 cranial nerve in the fetus. Its 
main side effect is ototoxicity.  
2.6.4. Pharmacological properties of individual ARV drugs (SAMF, 8th
 
 edition; 322-
328) 
Lamivudine- this drug is a NRTI used for the treatment of HIV infection, reduction of 
peri-natal transmission of HIV, post-exposure prophylaxis, in combination with other 
ARVs. Common adverse effects include peripheral neuropathy and pancreatitis.  
 
Stavudine- this drug is also a NRTI used for the treatment of HIV infection, in 
combination with other ARVs. Adverse effects include lipo-atrophy of the face and 
limbs, peripheral neuropathy, pancreatitis and other CNS effects such as headache and 
haematological side effects.  
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Zidovudine-this drug has the same indications as Lamivudine and is also a NRTI. 
Adverse effects are dose-dependent and are more frequent and severe in advanced HIV 
disease. Common haematological effects include anaemia, leucopenia or neutropenia. 
  
Efavirenz- this drug is a NNRTI used for the treatment of HIV infection, in combination 
with other ARVs. Adverse effects include hypersensitivity rashes and common CNS 
effects include abnormal dreams.  
 
Nevirapine- this drug is also a NNRTI and has been commonly used for the reduction of 
peri-natal transmission of HIV. Common adverse effects are rash which appear in the 
first six weeks of therapy.  
 
2.6.5. TB treatment phases 
Standard adult treatment regimens for newly diagnosed pulmonary TB patients start with 
an initial (or intensive) phase. This phase consists of four first-line drugs, which are 
rifampicin, isoniazid, ethambutol and pyrazinamide. These drugs are taken orally for two 
months. This is followed by a continuation phase of 4 to 6 months normally consisting of 
oral treatment with rifampicin and isoniazid. For re-treatment pulmonary TB patients 
classified as relapses or defaulters, the two phases are of longer duration as follows: 
 
The duration of the Intensive phase is 3 months with oral treatment consisting of R, H, E, 
and Z (see table 1.1) plus the intramuscular administration of streptomycin (S) during the 
first two months. The continuation phase consists of R, H and E given for 5 months. The 
aim of the continuation phase is to ensure that after reducing the bacterial burden of the 
infection, the TB patient is further sterilized against recurrence of the disease. 
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Revised Treatment Drug Regimens for TB patient  
This is a policy developed by the National TB control programme to give TB treatment 
seven 
• Dosages needs to be adjusted based on weight gain,  
days a week in both the intensive and continuation phases. The following are 
guidelines used in the treatment of TB for the year 2007: 
• Cure of the new Pulmonary TB (PTB) patients depends on taking Regimen 1 for 6 
months (Table 1), 
• Cure of the re-treatment PTB patients depends on taking Regimen 2 for 8 months 
(Table 2), 
• All TB patients should receive clinic DOT for the first 2 weeks
• TB patients must be supervised for the 
 of treatment, 
full duration
• All retreatment TB patients 
 of their treatment either at the 
clinic or by a community treatment supporter or a workplace programme, 
must
 
 receive treatment at the clinic Monday to Friday, 
for the first 2 months of the intensive phase. 
Regimen 1: New Adult Patients (SAMF, 2008:302) 
A new case is a patient who has never been treated for TB in the past or who has taken 
treatment for less than 4 weeks. Drug treatment must be taken for at least 6 months. 
 
Pretreatment Body 
Weight 
Two Months 
Intensive Phase 
Given Seven 
Four Months Continuation Phase Given 
Days 
A Week 
Seven Days A Week 
RHZE ( 150, 75, 
400, 275) 
RH ( 150, 75) RH ( 300, 150) 
30-37 kg             2 tabs              2 tabs            ------- 
38-54 kg             3 tabs              2 tabs             ------- 
55-70 kg             4 tabs              -----             2 tabs 
≥71 kg             5 tabs              ------             2 tabs 
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Regimen 2: Retreatment Adult Cases (SAMF, 2008:303) 
These are patients previously treated for TB or returning for treatment after cure, 
completion, default or failure. 
 
Pretreatment 
Body Weight 
Two Months Intensive Phase 
Given Seven
3
 Days A Week 
rd Month 
Initial 
Phase 
Seven
Four Months Continuation Phase     
Given 
 Days 
A Week 
Seven Days A Week 
RHZE 
(150,75,400,275) 
Streptomycin 
         [g] 
RHZE 
(150,75,400, 
275) 
RH 
(150,75) 
E 
(400)   
RH 
(300,150) 
E 
(400) 
30-37 kg            2 tabs        0.5        2 tabs   2 tabs 2tabs   ------- ----- 
38-54 kg            3 tabs        0.75        3 tabs   3 tabs 2tabs    ------ ----- 
55-70 kg            4 tabs        1.0        4 tabs   ------- -----  2 tabs 3tabs 
≥71 kg            5 tabs        1.0        5 tabs   ------- -----  2 tabs 3tabs 
 
2.7. Treatment adherence strategies 
From a public health sector point of view it is critical to stop both the spread of TB to 
others, and the development of drug resistance. A number of strategies aimed to improve 
adherence has been successfully implemented in hard-to-reach populations, especially in 
areas where TB is an endemic. These include the DOT and DOTS strategies.  
 
2.7.1. DOT versus DOTS 
Directly Observed Treatment (DOT) is currently the most recommended adherence 
method. DOTS on one hand stands for Directly Observed Treatment Short-course and 
refers to the WHO’s comprehensive internationally recommended policy package for TB 
control. On the other hand, DOT is an element of DOTS and is a strategy having all of a 
TB patient’s medicine doses observed by a designated person that could be a health care 
worker, or trained and supervised community member to help ensure adherence to 
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therapy (Practical Pharmacy for developing countries, 2008). The DOTS strategy has 
been implemented in SA since 1996 (Department of Health, 1996). 
 
2.7.2. Effectiveness and non-effectiveness of DOT 
DOT increases the likelihood that full treatment course will be completed from 61% to 
86% (The Merck Manual Professional, November 2005). The rapid decline of TB 
incidence rates in the United States from a peak of 10.5 cases per 100,000(1992) to 5.8 
cases per 100,000 (2000) has been attributed to DOT (Pedro C et al, 2003; 107). From 
1995 to 2000, the incidence rate of TB in the United States fell by an average of 7.8% per 
year (Chan ED, and Iseman MD, 2002). Even though the principles of DOT has led to 
significant treatment success rates for both TB and HIV diseases (Chaulk CP, and 
Kazandjian VA, 1998; Weis SE et al, 1994), the role of DOT within the TB/HIV co-
infection context still requires further evaluation (Pedro C et al, 2003;121).  
 
2.8. Clinical criteria for initiating anti-retroviral therapy (ART) in TB patients 
As at the time of this study, the guidelines for initiating TB treatment in HIV-positive 
patients are as follows; If the patients CD4 count is >200cells/mm3, ART is commenced 
after completing TB therapy provided that the patient fulfils the criteria above. In other 
words, the CD4 count must be < 350cells/ mm3 i.e. between 200 and 350cells/ mm3. If the 
CD4 count is <200cells/ mm3 then  ART treatment should be delayed until the intensive 
phase of TB therapy ( 2 months) has been completed unless the patient has other serious 
HIV- related illness or has a very low CD4 count ( < 50cells/mm3). In such a case, ART 
should be introduced once the patient is stabilized on TB therapy at around 2 weeks 
(SAMF, 2008). However, the 2010 guidelines states that the CD4 count should now be at 
250 cells/ mm3 to start ARV treatment (SAMF, 2010). The South African HIV Clinicians 
Society guidelines states that TB should always be managed by public sector TB clinics 
(The Southern African Journal of HIV Medicine, 2005: 26). Its guidelines for starting 
ART when patients are already on anti-TB therapy depends on the patients ART regimen 
and CD4 count. Both anti-TB therapy and ART are complex regimens that require 
regular monitoring. Co-infected TB/HIV patients receiving dual therapies would 
therefore rely on the pharmacist to optimize care provision.  
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2.9. Role of the Pharmacist in TB/HIV management  
 
In view of the increasing TB/HIV co-infection pandemic, the pharmacist is ideally suited 
to work alongside other health practitioners especially the nurse. The World Health 
Organization has supported the notion that pharmacists should expand their role in the 
general healthcare system. This entails interacting with the healthcare team, interviewing 
and assessing patients, making specific therapeutic recommendations, monitoring patient 
responses to drug therapy and providing drug information (World Health report, 2006). 
Pharmacists can also work alongside nurses to interview and assess patients, a role 
outlined by the Doncaster model and other authors (Dayton C.S., 1978; Andalo D, 2002). 
They can be flexible in adapting to different situations, which includes working outside a 
pharmacy setting with a range of HCP’s, and having direct TB patient involvement 
(Rennie, TW, and Bates, IP, 2009). 
 
Zappa (1999) conceptualised a new model for pharmacists in HIV management that 
concentrated on drug-related activities, information provision and patient confidentiality. 
Findings from the Van der Walt (2006) study indicated that other healthcare professionals 
perceived an expanded role for pharmacists in HIV management beyond that of a drug 
supplier (Zappa AJ, 1999; Van der Walt E, and Summers RS, 2006). The South African 
Pharmacy Council’s Position Paper clearly underpins the role and need of the pharmacist 
in TB management to help curb the epidemic (2003). However, documented evidence of 
a patient-centered role for pharmacists is not yet available. According to the Van der 
Walt’s study, a comparison of defined roles for pharmacists in HIV management is 
outlined in table 1.2 (Van der Walt E, and Summers RS, 2006).  
 
Table 1.2: Comparison of defined roles for pharmacist in HIV management  
Zappa (1999) SA Pharmacy Council 
Criteria (2003) 
Responses of Van der 
Walt survey (2006) 
Responsible for all drug-
related activities 
Supply ARV’s, manage 
tuberculosis and treatment 
of opportunistic infections 
Dispense medication 
Be aware of side effects and 
drug interactions 
Counsel patients on correct 
use of medication 
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Supply products, services 
and information in one 
place 
Provide prevention, 
treatment, care and support 
services 
Provide post-exposure 
prophylaxis 
Focus on education, 
prevention and screening 
programmes 
 
Provide voluntary testing 
and counselling 
Do pre-test counselling 
Include services of a 
nutritionist and nurse, and 
complement services 
provided by the medical 
doctor 
Monitor complications and 
referrals for medical 
intervention 
Pharmacies as HIV 
information centres 
Pharmacies as registered 
preferred HIV treatment 
providers 
Ensure patient 
confidentiality  
Ensure patient 
confidentiality and privacy 
 
While the literature underpins a role for the pharmacist, newly qualified graduates are 
also expected to be competent care providers in TB and HIV management. Therefore, a 
review of undergraduate pharmacy training would provide insight into current teaching 
on TB/HIV at an academic institution.   
The dynamic nature of the pharmacy profession necessitates continual revision of 
undergraduate training to meet both changing and challenging health needs (Smith, 
Coons & Quinns, 1990). The University of the Western Cape’s (UWC) School of 
Pharmacy‘s TB/HIV programme (2009) was reviewed for the purpose of this study. 
Section B 
2.10. Current teaching practice of TB/HIV at UWC School of Pharmacy 
In the UWC undergraduate pharmacy curriculum, basic pharmacology is introduced in 
second year. Systemic pharmacology taught in third and fourth (final) years covers a 
range of common clinical conditions including TB and HIV. Classroom teaching which is 
largely didactic is supplemented with practical exposure at hospitals and Community 
Health Centres. These consist of the Clinical Block and the Service Learning in- 
pharmacy modules. However, education about TB and HIV should extend beyond 
traditional didactic methods (Chaulet P, 2007). The objectives of the Clinical Block are to 
develop skills in assessing treatment plans, counselling of patients and interacting with 
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healthcare professionals at district and tertiary hospitals. Service learning provides 
opportunities for students to both deepen their mastery of the technical skills and 
knowledge-base in pharmacotherapy, pharmacy practice and pharmaceutics while also 
developing social responsibility among students. Final year students at CHCs and 
hospital pharmacies fill prescriptions, dispense, manufacture compound, and pre-pack 
medicines (Pollack S, 2008). 
2.11. Evaluation of the Service learning in- Pharmacy (SLIP) module at UWC 
An independent evaluation of the SLIP modules indicated that despite the fact that each 
student spends 3 weeks a year in hospital pharmacies through the SLIP programme, there 
is still the lack of “socially responsible, patient –centered” practice and direct interaction 
with patients, doctors, nurses, and other healthcare professionals (Pollack S, 2008). A 
further deficiency in the current SLIP program is that rotation of students is limited to the 
provincial hospitals and CHCs. Primary healthcare clinic that provides integrated care for 
TB and HIV patient’s i.e. ARV clinics are not included as learning sites.  
By interacting directly with patients in the clinics or private counselling area, students 
can obtain a deeper understanding of the range of barriers such as cultural, socio-
economic, gender, racial including those affecting HIV/AIDS and TB. From these 
patient-centered discussions, interventions can be developed to address the healthcare 
needs of diverse communities (Pollack S, 2008). Since learning generally occurs through 
experiencing the activities and cultural norms of the discipline, it is essential that students 
become exposed to real situations in TB and HIV clinics. Exposure of students to primary 
healthcare TB/HIV clinics will enable them to focus on the development of professional 
and social skills that are necessary in real life situations.  
TB and HIV impose an increasing burden on the health system. Complex drug therapies 
require regular monitoring of patients to prevent resistance and relapse.  Concerted 
efforts from pharmacists are required at primary healthcare clinics to screen, monitor and 
evaluate TB and HIV treatment outcomes. In preparing graduates for the work 
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environment, pharmacotherapy and service learning modules are cornerstone to 
developing knowledge and skills in clinic-based TB/HIV care.  
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CHAPTER 3: RESEARCH DESIGN AND METHODOLOGY 
 
This chapter outlines the research methods used in this study. I discuss triangulation as an 
approach used to combine data obtained from both quantitative and qualitative methods. I 
describe the study sites and provide an overview of the study population. The effect of 
the intervention (described in chapter 5) was evaluated using evaluation methods namely 
programme and summative evaluations. This chapter concludes with an algorithmic and 
schematic representation of the research design used in the different phases of this study.  
 
The primary aim of this study was to assess current practice patterns in the management 
of TB and HIV amongst co-infected patients (Phase I). The secondary aim of the study 
was to ascertain the need for an undergraduate TB/HIV clinic-based training for final 
year pharmacy students (Phase II). In order to meet these objectives it was necessary to 
engage with the management of the primary healthcare clinics at the City Health 
department of the Tygerberg Sub-district, Cape Town (2008). The researcher who is an 
academic intern at the School of Pharmacy, UWC required in-depth insight and 
knowledge into clinical procedures in TB/HIV primary healthcare clinics. A meeting was 
held to outline the purpose and objectives of the study, and to seek a participatory 
approach in implementing the intervention (chapter 4, section 4.1). A TB coordinator of 
the Tygerberg Sub-district was subsequently assigned to train the researcher using the 
same approach when training and updating clinical nurse practitioners at primary care 
clinics on TB and HIV care provision. The TB coordinator used the PALSA Plus training 
materials and training approach. The contents and training style of PALSA Plus is 
outlined in chapter 4.  
 
The main qualitative method of data collection was through interviews and participant 
observations whilst the quantitative data was collected from survey responses and these 
noted as numbers and analyzed. The research design chosen allowed the use of mixed 
methods throughout the different phases of study namely the pre-intervention, 
intervention and post-intervention phases.  
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Phase I study 
3. Description of research sites   
 
The study sites namely Ravensmead CHC, Delft South ARV clinic, and Elsies River TB 
clinic were chosen because they are located in the Northern suburbs and are of close 
proximity (about 25km) to the University of the Western Cape. Further, they are typically 
representative of care offered by most primary healthcare clinics in the Western Cape. 
Ravensmead CHC mainly provides care for TB patients and this site was used for the 
baseline study to assess current practice patterns in TB management (see chapter 4). Delft 
South ARV clinic provides integrated care for both TB and HIV patients and was used 
for implementation and evaluation of the intervention. Elsies River is mainly a TB clinic 
and caters for a very small number of HIV-positive patients and was used as an add-on 
site. A brief description of the community profile is provided for each of the research 
sites.  
 
3.1. Ravensmead Community 
Ravensmead community consists of predominantly lower income coloured earners whose 
language preference is Afrikaans. Ravensmead was chosen as a study site because it has a 
very high TB load. The rate of registered new-smear positive TB cases increased from 
228 per 100 000 in 1994 to 299 per 100 000 in 1998 and to 341 per 100 000 in 2002 
(Statistics South Africa: Western Cape, 2001; Western Cape Tuberculosis Programme, 
2002; Boon SD et al, 2007).  
 
3.1.1. Ravensmead CHC 
This CHC is targeted at TB patients however there is a small proportion of patients co-
infected with TB and HIV. The CHC operates 5 days a week but weekend TB regimen is 
given as packages to TB patients. 
 
Following the PALSA Plus training the researcher’s first clinical observation took place 
at Ravensmead CHC to obtain baseline knowledge and views about current practice 
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patterns in order to prepare for the pre-intervention, implementation of the intervention, 
and post-intervention phases of the study (see chapter 4).  
The Delft community is predominantly coloured (75%), with a minor population of Black 
Africans (25%). This community is split into two sections: Delft and Delft South.  There 
is a 44% unemployment rate from the economically active total population of 24,000. 
Over half (58%) of the residents have a yearly household income of R0 – R19,200 and 
over a third (38%) with R19, 201 – R76,800, an indication of the income disparity in this 
area. Many people in the community come from the Eastern and Western Cape provinces 
while others have immigrated from other African countries such as Nigeria and Somalia 
(www.capetown.gov.za/Censusinfo/Census2001/). 
3.2. Delft South Community 
The Delft South clinic was the main site used for this study because it is an integrated 
clinic that offers services for TB and HIV co-infected patients. The clinic has been active 
since June 2006 and provides care to about 150 clients per day.  The clinic has a total of 
five nursing sisters working five days a week, and a dedicated TB doctor that visits once 
a month.  It offers a nurse-based service with a promotive and preventative focus. About 
140-150 people are tested for HIV per month, with about 30 patients testing positive 
many of which are expectant teenage mothers.  The most common health problems 
handled by the clinic are HIV, TB, and sick babies especially in winter. The facility 
consists of 17 consultation rooms, three treatment rooms and ample waiting areas 
(www.capetown.gov.za/Censusinfo/Census2001/). 
3.2.1. Delft South Clinic  
In this study, patients were recruited and interviewed in one of the consultation rooms. 
Since clinic nurses and DOTS supporters use a dedicated TB room for consultation of TB 
patients exclusively, recruitment of co-infected TB and HIV patients in this study was 
done in the consultation room occupied by the adherence counsellor who usually attends 
to TB patients and co-infected TB/HIV patients. Delft South ARV clinic consists of 
English and isiXhosa speaking patients, it was necessary to contract a translator who is 
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fluent in both languages to assist with post-intervention data collection at the clinic 
because the researcher was fluent in only English. 
Elsies River is predominantly a coloured community (92%). The population has 
approximately 40,000 people, among which 34% are unemployed.  Generally, wages are 
low with majority of the income ranging from R0–R1, 600 per month.  Although the 
community has 14 primary schools and six high schools, problems with drug addiction, 
prostitution and alcohol abuse reduce the high school graduation rate 
(www.capetown.gov.za/Censusinfo/Census2001/). 
3.3. Elsies River Community 
A doctor visits the clinic once a week attending to only TB patients. Elsies River clinic 
offers family planning, HIV and TB testing and counselling, postnatal care, and basic 
health.  About 85-90 patients are tested for HIV per month, with an average of 5 testing 
positive per month. Relatively few patients test positive for HIV in Elsies River, but TB, 
STIs and teenage pregnancy are 
3.3.1. Elsies River Clinic  
very
The duties performed by the various HCP’s at Elsies River TB clinic were closely related 
to those performed by the HCPs at Ravensmead CHC. However, duties performed by the 
HCPs at Delft South ARV clinic were of no resemblance to those at Ravensmead and 
Elsies River clinics. The reason being that both Ravensmead and Elsies River clinics 
provided services to mostly TB patients whilst Delft South ARV clinic provided 
integrated care for TB patients (in the TB room) and those co-infected with TB and HIV 
(consultation rooms). 
 common in the area.  The staff roles and 
responsibilities at Delft South ARV clinic and Ravensmead CHC deviate slightly but 
generally duties are similar across both clinics.  
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Figure 3.1: Layout of Elsies River TB room  
                                                         Patient waiting area 
                                                             
 
  
 
 
       
      
 
 
 
 
   
 
 
 
 
 
 
The layout for Elsies River TB room is similar to that of Ravensmead TB room (see 
chapter 4, figure I) probably because both clinics are TB clinics and are staffed by mainly 
clinic nurses and DOTS supporters. The locker has four compartments numbered one to 
four. The first locker contains folders of patients attending the clinic daily. The second 
locker contains folders of daily patients and TB defaulters. The third locker contains 
folders of patients attending the clinic weekly, monthly and patients from other clinics. 
The fourth locker contains folders of patients receiving DOTS outside the clinic.  
3.4. Study population 
Patient recruitment from PHC clinics 
For phase I of the study, the study sample for assessing current practice in TB/HIV 
management consisted of TB patients from Ravensmead CHC, and TB/HIV co-infected 
patients recruited from Delft South ARV and Elsies River TB clinics. In addition, HCP’s 
namely the clinic nurse, adherence counsellor and TB doctor were approached to 
participate in this study. For phase II of the study final year pharmacy students were 
recruited from UWC. 
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Phase II study 
3.4.1. Recruitment of final year pharmacy students from UWC 
The final year pharmacy class of 2009 was made up of 72 students. Forty-four of these 
students were randomly assigned into 2 groups namely control and experimental groups. 
The control group had 37 students whilst the experimental group had seven students. The 
researcher approached a senior academic staff member and informed them about the 
purpose and objectives of the study. The academic staff member agreed to offer a 
teaching slot where half of the class was expected to undertake an assessment on TB/HIV 
management. The remaining half of the class had already been assessed in the first term 
and an assessment on TB/HIV was due for the remainder of the class. The purpose was to 
assess the current knowledge of TB/HIV and to determine the need for a clinic-based 
programme for undergraduate pharmacy students. The experimental group (n=7) students 
received an introductory clinic-based TB/HIV training during the July school vacation 
(2009) from the trained researcher. The control student group (n=37) students received 
the usual classroom based TB/HIV programme. It was not possible to obtain participation 
from the entire class because of the intensive academic programme.  
3.4.1.1. Inclusion criteria for clinic-based study 
Phase I study 
• TB and HIV co-infected patients attending a City Health clinic diagnosed and 
receiving treatment for at least 1 month ,  
• Other participants that provide health services at each of the primary healthcare 
clinics namely the clinic nurse, adherence counsellor and TB doctor. 
Phase II study 
• Final year pharmacy students from UWC (Class 2009). 
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3.4.1.2. Exclusion criteria for this study 
Phase I study 
• ARV pharmacist and children  
Children were excluded from this study because of the complexity involved with their 
management and drug therapy (see chapter 2, section 2.3). 
Phase II study 
There was no exclusion criterion. 
For Phase II of this study, final year pharmacy students from UWC’s School of Pharmacy 
(2009) were invited to participate to ascertain the need for a clinic-based TB/HIV 
training. The aims of the student’s assessment were to firstly ascertain their current 
knowledge on TB/HIV clinic-based management (see Appendix O, questions 1-19d) 
which served as the main quantitative data. The qualitative data was collected from 
questionnaires completed by the students (see Appendix O, questions 20-23). Their views 
on the potential role for pharmacists in a clinical setting were also explored.  
3.5. Mixed Methods 
For this study a combined research methods termed mixed methods was used. A 
combined method study can be described as one in which a researcher uses multiple 
methods of data collection and analysis. An element of combined method could be 
mixing between methods, drawing on both qualitative and quantitative data-collection 
procedures and one such example is triangulation.   
 
3.6. Triangulation as a combination of qualitative and quantitative approaches 
Triangulation was used as a way of combining the quantitative and qualitative 
methodologies. Padgett defined methodological triangulation as the use of mixed 
methods to study a single topic (1998:97) and further describes triangulation in 
qualitative research as the convergence of multiple perspectives that can provide greater 
confidence that what is being targeted is accurately captured (1998:32). Most authors 
agree that in real life, most human based research utilize both quantitative and qualitative 
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methodology (De Vos AS et al, 2005:361). Both quantitative and qualitative 
methodologies are used in programme evaluation. 
 
3.7. Programme evaluation 
Programme evaluation as defined by Patton (2002:10) is the systematic collection of 
information about the activities, characteristics and outcomes of programmes to make 
judgment thereof, improve its effectiveness and/or inform decisions about future 
programming. Programme evaluation assumes the prior existence of a programme or 
“intervention” designed and developed by someone else, long before the evaluator ever 
entered the field (De Vos AS et al, 2005:367). The programme is the “intervention” and 
the evaluation is based on an existing programme. The intervention is the independent 
variable that is being investigated whilst the dependent variable is the criterion with 
which the independent variable is being evaluated (Fox W, and Bayat M, 2007:79). 
 
For the phase I study, the programme evaluation focused on a clinic-based intervention 
designed for potential use by trained pharmacists in TB/HIV management. The 
intervention consisted of a trained researcher who made use of a specially designed 
TB/HIV clinic record card. For the phase II study, the intervention programme consisted 
of exposure to an introductory clinic-based session on TB/HIV management.  
 
The overall aim was to determine if a clinic-based TB/HIV programme would make a 
difference to the quality of care at primary healthcare clinics (phase I study) and if an 
introductory clinic-based session would demonstrate application of theoretical concepts 
among students (phase II study).  
 
3.8. Summative evaluation 
Summative programme evaluation measures the effectiveness of a programme and is 
more quantitative. Successful programmes may be replicated and implemented if the 
designer(s) of the programme can demonstrate scientifically that the programme had 
positive outcomes.  Summative evaluation compares the “intervention group” with the 
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“no intervention group” to assess any positive change in the former (Kagee A et al, 2006: 
61). 
 
Since phase I of the study focused on assessing TB/HIV management among patients 
who received the intervention, quantitative data obtained from those who received the 
intervention were compared with those patients who did not. Therefore the summative 
evaluation was employed to assess care provision between the two groups. For phase II 
of the study scores of students who received the introductory clinic-based session and 
those who received the usual classroom based teaching on TB/HIV management were 
assessed.  
 
3.9. Quantitative research design 
A research design should be tailored to the exact needs of the problem. Research designs 
have two essential components. The first is observation and the second is analysis of the 
relationship between variables. Three categories of research design can be distinguished 
and are named in increasing order of scientific rigour. They are pre-experimental design, 
quasi-experimental design and lastly the experimental design. The pre-experimental 
design is least likely to establish a clear relationship between the independent and 
dependent variable. Though the experimental design was developed before the quasi-
experimental design, the latter accommodates social reality constraints, thus quasi-
experimental designs are amendments to stricter experimental designs (Kagee et al 2006: 
75-76). An example of an experimental design is the Solomon Four-group design (details 
outlined in 3.9.2). It consists of the following variables denoted as follows: 
 
R = random assignment of subjects to each group 
O = observation or point where data is collected as a dependent variable and  
X = exposure of a group to an independent variable (e.g. intervention) 
The purpose of the observation is to measure the effects of the intervention. 
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3.9.1. Randomization 
Most experimental designs make use of randomization to create two or more groups. The 
use of randomization ensures that the groups’ characteristics are identical. Randomization 
requires that every subject involved in a study has an equal chance of being assigned to 
any of the groups of the study. This can be achieved by first identifying the entire group 
of subjects, then randomly dividing the group into two or more subgroups depending on 
the chosen design (Kagee A et al, 2006; 75-88). Random selection means that each 
member of the population has an equal chance of being selected into the sample. The 
advantage of randomly generated groups is that the researcher starts the experiment with 
two (or more) equivalent groups. If only one group is subjected to the treatment, the 
researcher can be reasonably sure that any difference between the groups thereafter is due 
to the effects of the treatment. The group that does not receive the intervention is called 
the control group, while the group that receives the intervention is called the experimental 
group. 
 
For phase I of the study patients who attended the clinic for the day and met all the 
inclusion criteria were randomly selected. For phase II, a convenient sample of students 
was used since over half of the class was available to participate in the usual method of 
assessment (n=37) and a smaller group received the introductory clinic-based training 
(n=7).  
 
3.9.2. Solomon Four-group design 
This design is used when the effect of a pre-test on subjects is of concern. It is attractive 
to researchers because it accounts for each alternative of the pre- and post- testing. This 
design controls for most threats due to internal validity (Kagee A, Higson-Smith C, Bless 
C, 2006; 88). Campbell and Stanley rated this design as prestigious and felt it was the 
first to explicitly consider external validity factors (1963; 24). Its major drawback is that 
four separate groups are needed and thus will require more time, energy and resources to 
implement his design. Furthermore, statistical analysis of this type of design has been 
shown to be complicated (Saber L, 1985). There are two experimental groups (E) and two 
control groups (C), but the pretest is received by only one of each of these groups (Table 
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3.1). Group 1 and 3 are experimentals while Group 2 and 4 are controls. All the groups 
receive the post-test. 
 
Table 3.1: Solomon four-group design 
Group 1: E1  (experimental)         R         O1         X       O2         (Pre 
Group 2: C
+ Intervention + Post) 
1  (control)                  R         O3                   O4 
Group 3: E
     (Pre + Post) 
2                                  R                      X        O5         
Group 4: C
(Intervention + Post) 
2                                  R                                 O6         (Post only) 
 
In this study, data obtained from patients at Ravensmead CHC served to provide baseline 
information so that the researcher could firstly familiarize herself with clinical procedures 
thus the research design did not apply (see chapter 4). Therefore the Ravensmead CHC 
patients only received the pre-questionnaires. The patients at Delft South ARV clinic 
were grouped into either experimental or control groups. The experimental patients at 
Delft South clinic received the pre-questionnaires, intervention and post-intervention 
questionnaires whilst experimental patients at Elsies River clinic only received the 
intervention and post-questionnaires. An algorithmic framework of the research design is 
outlined in table 3.2.  
 
3.10. Quantitative data collection methods 
Quantitative data collection methods used for quantitative processes can be categorised 
into questionnaires, checklists, indexes, and scales. Questionnaires were used to collect 
data for this study.  
 
A questionnaire is a set of questions on a form which is completed by the respondent in 
respect of a research project (New social work dictionary, 1995; 51). Questionnaires are 
distinguished from research interviews since the latter is a form of data gathering within 
the qualitative approach. There are five types of questionnaires namely mailed, 
telephonic, self-administered, questionnaires delivered by hand and group-administered 
questionnaires.  
 
 
 
 
 
 36 
With regard to self-administered questionnaires, the researcher (or fieldworker) limits 
his/her own contribution to the completion of the questionnaire to an absolute minimum. 
The researcher remains in the background but can encourage the respondent with a few 
words to continue with their contribution, or lead them to the subject (De Vos AS et al, 
2005:166-168). For phase I of the study, self-administered questionnaires were handed to 
the patients (see Appendix A) who completed them independent of the researchers’ input. 
The researcher was only available to clarify terms or phrases from the questionnaire, and 
this was done in a neutral manner. For phase II of the study, quantitative scores were 
obtained from the assessment that students had undertaken.    
 
3.11. Sampling 
Before understanding the concept of sampling one must define certain terms such as 
population and sample. The population is the entire set of subjects or people to which the 
research is focused. A sample is part of a population to be included in a study i.e. the 
subset of a whole population which is investigated by the researcher and whose 
characteristics will be generalized to the entire population (Bless C, and Higson-smith, 
2000:85). Sampling is the study of the relationship between a population and the samples 
drawn from it thus means leaving certainty for probability. The major reason for 
sampling is feasibility (i.e. probability) because it is impossible to cover a total 
population (i.e. certainty) (Yates SJ, 2004: 25). 
 
A large sample provides conclusions that are more reliable and valid than a small sample 
even though the former is more costly (Schaller, 1992:66; Bless C, and Higson-smith, 
2000:93; Mitchell M, and Jolley J, 2001: 496). The researcher must be careful not to use 
a very large sample size and vice versa. The sample size can impact on the statistical test 
by making it insensitive (small sample size) or too sensitive (very large sample size). 
Factors that influence the size of a sample are: heterogeneity of the population, desired 
degree of accuracy, type of sample, available resources, and the number of variables in 
which data is grouped (Singleton R et al., 1988: 158; Neuman WL, 2003: 232).  
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The sample size for the primary study (Phase I) was calculated by using the Epi Info, 
Statcalc version 6 November 1993. A 95% confidence interval was used, and the ratio of 
exposed to unexposed patients was set as 1:1. The sample size was calculated to be 56 
patients when the frequency of disease (in percentage) of the unexposed group was put at 
30% and percentage of exposed group was put at 70%. However, 98 patients were 
recruited for this study to cater for external validity and reliability. The sample size for 
the secondary phase (Phase II) depended on student availability. The student sample 
undertaking the usual method of assessment was 37, and those who received the clinic-
based training was seven.  
 
3.12. Qualitative data collection methods 
A combination of two procedures was used when collecting qualitative data namely 
interviewing and participant observation and these were advantageous because of the 
ease in cross-checking and validating findings. Each of these procedures has its strengths 
and weaknesses but by using triangulation the strengths of one procedure compensates 
for the weakness of the other (Patton MQ, 2002:306).  
 
For Phase I of the study, prior to the interview process at Delft South ARV clinic, the 
questionnaires required translation form English to isiXhosa. A translator fluent in both 
English and isiXhosa language was contracted to assist with pre- and post intervention 
data collection at the clinic. The researcher ensured that the interview did not impact on 
service provision at the clinic. 
 
3.12.1. Interviews 
Qualitative studies use either unstructured or semi-structured interviews to collect 
information about the study sample. Confusion sometimes arises between unstructured 
and semi-structured interviews as some books use both terms interchangeably. 
Unstructured interviews are in-depth interviews whilst semi-structured interviews are 
those organised around areas of particular interest, while still allowing considerable 
flexibility in scope and depth (Morse JM, 1991: 189).  
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In the Phase I study, the interviews took place within the clinic setting of each site. 
Participants consisting of patients and HCP’s were rarely distracted as the clinic 
environment provided adequate privacy which was non-threatening, and readily 
accessible. 
 
Semi-structured one-to-one interviews 
With semi-structured interviews, the researcher makes use of an interview schedule 
which contains predetermined questions to guide the interview. In Phase I of this study, 
semi-structured interviews were used to ascertain participant’s (patients and HCP’s) 
views and perceptions. It was used because it provided flexibility for both the participants 
and the researcher. In preparation for such interviews, questions are written to guide the 
enquiry process. It forced the researcher to think of difficulties that might be encountered, 
for example the type of vocabulary used. In this study, the technique known as funneling 
was used because certain questions were dichotomous (Yes/No) but still remained open-
ended. For Phase II of this study, semi-structured interviews were not applicable.  
 
3.12.2. Participant observation 
This is a typical qualitative approach to collect data. In participant observation, data 
gathering is based on the actual observation of subjects and taking field notes. Participant 
observation at designated research sites provides an opportunity for rich contextual 
information to be collected and recorded in the form of field notes: Where appropriate, 
actual quotations are provided. The researcher is involved in the daily behaviour, actions, 
interactions, and events of subjects by taking notes in a semi-structured manner in order 
to gain additional insight (Muller JH, 1995; Shephard M, 1995; Creswell JW, 2003; 
Ritchie J, and Lewis J, 2003).   
 
In this study (Phase I), I observed interactions and practice patterns that occurred 
routinely during patient-HCP consultations and between HCP’s. The observations 
focused on the screening procedures for patients with TB and HIV, history-taking, 
counseling on medicine use, and provision of follow-up care. I noted these observations 
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in detail in a research journal especially during the interview process that took place in 
the clinic.  
 
3.13. Data input and analysis 
Data input, analysis and calculation of sample size was obtained by using the Epi Info 
2002 package. For Phase I of this study, responses obtained from pre-intervention 
questionnaires, intervention (trained researcher using modified clinic record card) and 
post-intervention questionnaires were first coded, then data entered into the Epi Info 
spreadsheet and analyzed. Proportions for each parameter were obtained and cross 
comparisons of common parameters were obtained to determine the effect of the 
intervention on the quality of care provision among TB/HIV patients.  
 
3.14. Validity and reliability 
Validity means that a measurement represents what it is supposed to. There are six types 
of validity namely face, construct, predictive, concurrent, internal and lastly external 
validities. Internal validity tests instruments used to measure whether a phenomena is free 
from bias. External validity measures how far the research can apply outside the research 
setting. Reliability refers to consistency of a test, model or measurement having the same 
outcome at different times. Since this is an exploratory study (Phase I and II) attempts to 
adhere to valid approaches were made where possible in each phase of the enquiry 
process (Kagee A et al, 2006; Fox W, and Bayat M, 2007).  
 
3.15. Ethics 
Ethical clearance was obtained from the UWC Research Ethics Committee (May 2008). 
Approval to engage with clinic patients and staff was obtained from the management of 
City Health, Tygerberg Sub-district, Cape Town (April 2008). Written information about 
the aim and objectives of the study was provided to the participating patients in either 
English (pre-questionnaires) or isiXhosa (post-questionnaires) depending on language 
preferences. Written consent was subsequently obtained from both the patients and 
HCP’s who agreed to participate. Both verbal and written communication to all 
participants before commencement of each phase of the study indicated that participation 
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was completely voluntary, confidential and anonymous. Participants were informed that 
they had the option to leave at any phase of the study.  
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Table 3.2: Outline of research design and methods used for this study 
1. Phase I: 
Primary aims: Assess current practice patterns at Ravensmead CHC(chapter 4) 
Baseline study  
      
TB coordinator offers        
clinic-based training to  
the researcher.                                                
   Proceeded to 
 
 
 
 
• Qualitative and Quantitative data obtained from this baseline study (one week) 
was used to design the intervention tool and modify the pre-intervention 
questionnaire for further investigation at Delft South ARV and Elsies River TB 
clinics. 
 
------------------------------------------------------------------------------------------------------------ 
1.1. Pre- intervention at Delft South ARV clinic  
Aim: to assess patient perceptions towards pharmacist’s involvement in TB/HIV 
management and knowledge of their drug treatment.    
                         
• Qualitative data was collected from participant by using observation technique 
and interviews. 
 
• Quantitative- patient’s face-to-face unstructured questionnaires (Appendix A) and 
HCP questionnaire was used to assess patient perceptions towards pharmacist’s 
involvement in TB/HIV management and knowledge of their treatment 
(Appendix B). 
 
  
------------------------------------------------------------------------------------------------------------ 
1.2. Implementation of Intervention tool at Delft South and Elsies River clinics. 
(chapter 5) 
• Intervention conducted over 4 months (July–October 2008). 
 
• Intervention tool was adapted from patient TB clinic record card (GW 20/12, 
2002) and modified by researcher to cater for co-infected patients. 
 
 
• HCP questionnaire to assess their perceptions and attitudes towards pharmacist’s 
involvement in TB/HIV management (Appendix B). 
 
 
 
 
Trained 
Researcher 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ravensmead    
CHC 
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  Post-intervention phase 
• Conducted at Delft South ARV and Elsie’s river clinics. 
 
• Post-intervention questionnaires (Appendix C) were designed by 
researcher to assess receptivity of the intervention tool by co-infected 
patients.  
 
------------------------------------------------------------------------------------------------------------ 
      2.     
Secondary aim: assess the need for a clinic-based TB/HIV among final year 
pharmacy students at UWC (chapter 5) 
 Phase II 
• Assess students’ current knowledge of TB/HIV management (June 2009). 
 
• Offer introductory clinic-based training to seven final year pharmacy students. 
 
• Assessed results of both trained students (experimental) and students who 
received no training (control). 
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CHAPTER 4: BASELINE STUDY  
 
In this chapter, I describe the clinic-based training in TB/HIV management called 
PALSA Plus which I received from a district TB co-coordinator. I discuss the baseline 
study which was conducted at Ravensmead community health centre (CHC). I provide a 
demographic profile of the Ravensmead community and a description of the Ravensmead 
CHC. I also discuss my introduction to the clinic and its staff members. I outline the 
design of the face-to-face questionnaires directed to the patients, and HCP’s. I discuss the 
interview process, data collection process and conclude with findings from the baseline 
study which served as the preparatory framework for the subsequent study phases.  
4. PALSA Plus Training  
I describe the role of a district TB coordinator and the clinic-based PALSA Plus training 
approach which I received from her.  
4.1. Role of a District TB coordinator 
Depending on the size of the district and number of staff available, a district TB 
coordinator may be one person or a team of people. Therefore, the person or team 
responsible for TB control at the district level is called the district TB coordinator. The 
coordinator is usually a physician or a nurse and reports to the district medical officer 
(DMO) and is supervised by the provincial TB coordinator (WHO, 2005). A district TB 
coordinator typically conducts a clinic-based training on guideline implementation in 
TB/HIV management for primary care nurse practitioners. The district TB coordinator is 
responsible for updating nursing staff on latest protocols and guidelines as stipulated by 
the Department of Health, Provincial government of the Western Cape. Other duties 
include supplying anti-TB drugs, training health workers to prepare them to identify TB 
suspects, planning, organizing, implementing, and evaluating activities of a district TB 
control programme.  
A telephonic conversation was arranged with the then district TB coordinator of the 
Tygerberg sub-district to discuss potential training dates. The training started on the 17th 
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of April 2008 and took place at the UWC’s School of Pharmacy building. The three 
training sessions which lasted for approximately 30-45 minutes took place in a private 
consultation room situated in the first floor of the building. This venue was chosen to 
avoid potential disruption to the training sessions. The first session focused on TB 
symptoms and diagnosis. The second session emphasized the inter-relationship between 
TB and HIV. The last session was aimed at the treatment approaches and protocols for 
both conditions.  
PALSA Plus is a training programme directed to nurse practitioners and aimed at the 
management of patients with TB, STI, HIV including other respiratory problems (see 
Appendix C). “PALSA” is the acronym for Practical Approach to Lung Health in South 
Africa and “Plus” refers to the inclusion of HIV/AIDS management. The PALSA Plus 
approach condenses the national guidelines and the standard treatment guidelines into a 
desktop manual format which enables trained clinical nurse practitioners to screen, 
diagnose and treat a patient who presents with respiratory symptoms at the clinic (Stein J 
et al, 2008). The PALSA Plus manual follows an algorithmic system for the diagnosis 
and treatment of TB that can be followed in a step-wise approach. This training is offered 
in primary health care clinics and its major goal is to standardize care across the entire 
Western Cape. Notable pages from the 2007 PALSA Plus manual that are pertinent to 
this study include 6, 7, 8, 9, 15, 16, 17, 19, 20, and 21 (see Appendix C, pages 145-154). 
In addition a TB treatment wheel which forms part of the PALSA Plus material is used as 
a tool to encourage follow-up care. 
4.2. The TB Treatment Wheel  
The TB treatment wheel (Appendix D, Department of Health, 2008; 
http://www.coregroup.org/storage/documents/Workingpapers/Union_Meeting_Rpt_TB_2
007.pdf) was developed to assist healthcare workers identify return dates for TB patients. 
The wheel serves as a guide for patients on Regimen 1 and 2. Healthcare workers can 
note the dates on which new and retreatment TB patients on regimen 1 and 2 should be 
recalled for sputum collection and indicate the termination date of their treatment. The 
information is then entered in the patients’ clinic record cards.  
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The length of TB treatment can be prolonged in certain types of TB if the patient does not 
respond to treatment, or defaults during the course of treatment. This wheel also serves as 
a reminder to offer HIV testing to all TB clients. The combination of drugs to be 
administered during each phase of treatment is also noted on the wheel. 
The TB treatment wheel is designed around a circular base. Around the rim is a calendar 
showing the days and months of the year. A central rotating wheel is marked with arrows, 
which point from the centre outwards to the calendar. The TB treatment wheel is double 
sided. On one side of the wheel are dates for enrollment of new TB patients while on the 
other side are the dates for re-treatment patients. On each side the inner wheel has arrows 
for the date treatment started, 2 and 3-month sputum tests, 5 and 7-months sputum tests 
and 6 and 8-months treatment termination dates. These arrows are a fixed, and at a 
calculated distance.  
Form my theoretical knowledge of TB and HIV as an academic intern the PALSA Plus 
training served as a preparatory platform for my entry into a City Health clinic. It 
provided me with the practical perspective needed for clinic-based management of 
respiratory diseases such as TB. It also provided me with the skills and awareness needed 
to embark on my clinic visits.  
4.3. BASELINE STUDY 
4.3.1. Description of baseline study site 
 
Ravensmead as a community consists of predominantly lower income coloured earners 
whose language preference is mainly Afrikaans. The demographic profile of the 
Ravensmead community is outlined in Table 4.1. 
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TABLE 4.1 
Demographic Profile (Gender, Ethnic Group, and Language) 
RAVENSMEAD 
Male Female Total 
ETHNIC GROUP    
African/Black 93 102 195 
Coloured 11,526 12,682 24,208 
Indian/Asian 41 37 78 
White 35 30 65 
Unspecified 266 309 575 
Total 11,961 13,160 25,121 
LANGUAGE    
English 793 916 1,709 
Afrikaans 11,044 12,106 23,150 
Xhosa 3 6 9 
Other  14 14 28 
Unspecified 107 118 225 
Total 11,961 13,160 25,121 
Compiled by Urban Policy Unit from the 1996 Census data supplied by Statistics South 
Africa. 
 
The baseline study took place over 5 days at the TB room situated within the 
Ravensmead Community Healthcare Centre (CHC). The study began on the 28th of April 
and ended on the 2nd
 
 of May 2008. 
4.3.2. Selection of site to conduct baseline study 
Ravensmead Community Healthcare Centre (CHC) lies in close proximity to the 
University of the Western Cape (UWC), serving as an appropriate site to conduct the 
baseline study. Three key staff members that provide healthcare are; a nursing sister (TB 
nurse), a DOTS supporter (administrative support staff) who attends to TB patients on a 
regular basis and a doctor (TB medical officer) who attends to patients only on a 
Monday. TB services carried out at the Ravensmead TB room include screening, 
provision of TB treatment by both the nurse and DOTS supporter, and diagnosis of TB 
which is exclusively performed by the TB nurse.  
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I familiarized myself with the screening tool used by the clinic nurse to diagnose new TB 
suspects. This tool is used for routine clinical procedures and its design is adapted from 
PALSA Plus (see Appendix E). The history section of the tool can be completed by an 
administrative support staff such as the DOTS supporter whilst the diagnosis and action 
section can only be completed by the TB nurse. The doctor’s assessment is required when 
diagnosis is uncertain or the patient is smear negative and still symptomatic. The TB 
nurse is also expected to complete a short questionnaire on socioeconomic status, 
substance abuse, other underlying conditions, use of contraceptive methods and chronic 
medication.  
 
4.3.3. Entry into TB clinic 
I provide a brief description of my attire, the TB consultation room, meeting with the 
nursing staff and access to patient folders. 
 
4.3.3.1. Attire 
During my visits to the clinic, I opted to wear my white, short sleeved clinical coat 
mainly to differentiate myself professionally from the other staff members. I wore my 
nametag with the UWC logo at all times to enable people identify me. I adhered to a 
professional code of conduct. A protective clinical mask was worn properly at all times to 
avoid risk of infection when interfacing with patients diagnosed with TB. 
 
4.3.3.2. Contact with clinic 
I telephoned the sister-in-charge to arrange an introductory meeting.  A day was 
confirmed a week later.  In our meeting, I outlined the objectives and focus of my study. 
She gave me verbal consent to conduct my baseline study at the CHC.  I felt assured that 
all was on track up until my first interaction with the nursing sister. 
 
4.3.3.3. Initial meeting with nursing staff members 
My first visit to the clinic seemed unexpected to the clinic staff. The staff members were 
surprised by my presence and as result I could not engage with patients or have access to 
patient folders, thereby negating the purpose of my visit. Having confirmed my visit with 
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the sister-in-charge four days beforehand, it seemed evident that the clinic staff were not 
informed of my proposed visit. However, on the second day, I re-introduced myself to the 
staff and outlined the objectives of my study where an improved rapport was imminent.  
 
4.3.3.4. DOTS supporter 
I worked closely with the DOTS supporter during the duration of this baseline study, and 
below is a brief overview of how DOTS supporters are chosen in SA, the training they 
receive and duties they perform. These duties may deviate slightly across different sites 
depending on staff competence and patient load.  
 
Overview 
TB DOTS supporters are required to be accessible to patients. They are recruited from 
specific areas where there is a high density (caseload) of TB. They assist clinic nurses 
with their caseload of TB and this has been proven to be effective in making contact with 
potential patients. Candidates need to be reasonably mature, as some older patients do not 
like being supervised by younger people. Potential DOTS supporters should be 
functionally literate to keep records of dealings with patients (Dick J et al. 2005). 
 
DOTS supporter training  
The introductory training for DOTS supporters varies from site to site and ranges from 
five days to five weeks. The training covers aspects about being a DOTS supporter, 
details about TB as an illness, HIV/AIDS, and general health issues such as hygiene and 
nutrition. Many DOTS supporters have little formal education, with only a few 
completing secondary school (Dick J et al., 2005). 
 
Duties of DOTS supporter 
1. Collect medication each month from the clinic nurse. 
2. Check that patients take their medications. 
3. Record dose on TB clinic record card. 
4. Encourage non-adherent patients to adhere to treatment program. 
5. Remind patients to attend the doctors’ appointment. 
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6. Ensure that patients go to clinic and, 
7. Provide two-and five months follow-up sputum regimen. 
 
4.3.3.5. Access to patient folders 
Access to patient folders not only validated patients responses to the questionnaire, 
(Appendix A), but provided some degree of reliability about their medical and treatment 
histories. For example, some patients would not mention other chronic conditions that 
they have been diagnosed with other than TB. Only after checking their folders, such 
information could be retrieved so access to patient folders helped to eliminate biased 
reporting amongst patients, and authenticate their medical history.  
 
From my professional working relationship with the DOTS supporter I realized that their 
scope of practice is crucial to understanding barriers to treatment adherence. It provided 
me with the opportunity to engage directly with TB/HIV patients where I was able to 
access patient folders for information, conduct my one-to-one interviews, and observe the 
DOTS procedure personally amongst others.   
 
4.4. DESIGN OF QUESTIONNAIRES 
A questionnaire was designed for patients (Appendix A) and healthcare providers 
(Appendix B). Both questionnaires, were adapted from a previous pilot study (Bhawan D 
et al, 2007) and outlined information such as a title, official UWC logo, contact details, 
sub- headings, a brief description of the study, patient’s and healthcare provider’s (HCP) 
consent and lastly the date.  
 
4.4.1. Patient questionnaire 
The patient questionnaire comprised of 31 questions which were grouped into 5 
categories lettered A-F. Category A aimed at ascertaining the patient’s background 
information such as the folder number, demographics which included the gender, age, 
race, home language, highest education, residential status, employment status, living 
conditions, and socioeconomic status. Category B focused on the medical history of the 
patient with regards to TB. Questions were designed to assess the knowledge and 
 
 
 
 
 50 
perceptions of patients towards TB e.g. In your view, is TB contagious? Category C 
assessed the symptoms the patients experienced and what they would do if and when the 
discomfort became unbearable. Category D focused on drug treatment, namely the drug–
readiness training programme, duration of treatment, attitude and views towards 
treatment. Category E focused on the patient’s lifestyle such as their social habits and 
behaviour. Category F was reserved for counseling and the patient’s opinions on the 
perceived role of the pharmacist with regard to their TB/HIV side effects. 
 
4.4.2. HCP questionnaire 
The aim of this questionnaire was to explore current practice patterns of HCP’s namely 
nurses and doctors who provide TB/HIV care to patients and to elucidate a role for the 
pharmacist. The HCP’s questionnaire consisted of 14 questions with neither categories 
nor groupings. Enquiry was made into their qualification, TB care experience, materials 
used to screen and treat for TB, protocol used, and how they coped with the workload. 
Pharmacists were not included as a target group for this study because the Van Der Walt 
study (2003) conducted amongst Western Cape pharmacists clearly indicated that they 
were willing to explore an expanded role in HIV management.  
 
4.4.3. Layout of the questionnaire (Appendix A and B) 
Questionnaires were printed in English, and were printed back to back on white paper. 
The active voice was used at all times. Uniformity was maintained throughout both 
questionnaires with regard to formatting. Arial (bold) font size 14 was used for the main 
heading which was in capital letters and was also justified, centered, and bolded. In order 
to demarcate the consent form from the questions, a bold line was ruled above them. Sub- 
headings had font Times new roman (bold) with font size 12. Keywords were italized 
with font Times new roman and size 12. The boxes had 0.5 point line width, single solid 
line and an Arial border. The text was typed using font Times new roman size 12 and 
contained 718 and 403 words for the patient and HCP questionnaires respectively. The 
paragraphs had mixed line spacing. The consent form was single spaced whilst the rest of 
the questionnaire was exact. There were no borders included because it was a scientific 
research. All pages were numbered at the bottom with a centered alignment.  
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4.5. The TB consultation room 
The TB room was a small, well-ventilated room located at the airy part of the CHC. The 
TB room had two doors that allow fresh air in to prevent the spread of TB. A small 
private area, secluded with an opaque curtain was used to administer streptomycin 
injections. Because the TB room itself is limited in space, the patients waiting area is 
situated just outside the room which is justified as overcrowding is a risk factor for the 
spread of TB. On entering the TB room, eye catching posters were mounted on walls 
aimed at low-literacy patients. They contained information on TB management that was 
written in simple language for the English and Afrikaans speaking patients. Within the 
TB room was a small area reserved for DOTS patients to drink their medication. A sink 
located at the corner of the room is used by staff to wash hands after the administration of 
medications. A bathroom scale for weighing the patients is usually kept under the nurse’s 
table. 
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Figure 4.1: Layout of Ravensmead CHC TB room 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Waiting        
area for 
patients 
        
        
Note: Numbers 1-5 indicates but is not limited to patient route within the TB room.  
 
4.6. Patient interview process and data collection 
Patient’s interviews were largely dependent on the availability of the DOTS supporter. 
Patients reported to the clinic between 7am-8am because the DOTS supporter was only 
available from 9am to 11am (for two hours only) therefore her presence was crucial to 
recruit patients and obtain a reasonable sample size of 12. Since I am English speaking, 
and the DOTS supporter is fluent in both Afrikaans and English and very familiar with 
the clinic procedures, she served to streamline the recruitment and interview process. 
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4.7. Sample size 
The sample size was calculated from the present population of patients with active TB at 
Ravensmead CHC (2008).  
Population of TB patients (sample) = 52 (active TB) 
10% of sample population = sample size 
Therefore: 10/100 X 52 = 5.2 
                                      n= 5.2 
 
Some methodologists suggested that 10% sample of a known population has become a 
convention which serves as a handy rule of thumb for random sampling (De Vos AS et 
al, 2007:197), therefore 10% of the sample was enough to control for sampling errors 
(Seaberg, 1988:254; Grinnell, Williams, 1990:127). For this baseline study, sample size 
was estimated at 6 patients; however 12 patients were recruited to arrive at more 
conclusive findings.  
 
4.8. Recruitment process 
At recruitment, TB patients were assured that all information would remain strictly 
confidential and that their participation was completely voluntary. After verbal 
agreement, patients signed a consent form. In keeping with routine clinical procedures, a 
standard approach was used for all interviews. After the TB patients took their daily 
medications under the supervision of the DOTS supporter, they were escorted to the 
private consultation room where I was also located. The researcher greeted the TB 
patients, provided an overview of the study and received verbal and written consent for 
their voluntary participation. The baseline questionnaires were completed with assistance 
from the DOTS supporter when the need arose. All the patients were thanked for their 
time. 
 
I ensured that consistency was maintained when interpreting each question to the patients 
by cross-checking patient responses to randomly chosen open-ended questions from their 
TB record card. All the questions under category A were closed-ended questions and did 
not require any interpretation. They were asked to tick the options that applied to their 
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individual situation. There was a box available for “Other” which meant if their answers 
was not part of the options listed, then they could provide their personal ones. I made sure 
to avoid using ambiguous words that would have different meanings to different patients.  
Questions such as number 3, 8a, 8b, 12, 16, 18b, 26, 27, 30 and 31 (Appendix A) were 
targeted at getting opinions from the TB patients. The patients were provided with a pen 
to complete the questionnaire and each interview lasted for about 5-7 minutes depending 
on their level of understanding. At the end of each interview, the patients were thanked 
and wished well with their treatment. 
 
Self-administered questionnaires were completed by the DOTS supporter and clinic nurse 
to obtain their views and perceptions towards the pharmacist involvement in TB/HIV 
care. As opposed to the patient data collection process that required a standardized 
interview process, the HCPs simply completed the questionnaires and handed it back to 
the researcher. Responses obtained from the questionnaire collectively were noted as the 
HCP results (details in section 4.11).  
 
4.9. Results 
The results obtained in the baseline study were from mainly TB (and some HIV-positive) 
patients and HCP’s. Quantitative data was obtained from face-to-face interviews with 
patients, while my observations of the DOTS procedure with patients provided the 
qualitative data.  The HCP results presented in table 4.3 below are only qualitative.  
 
4.9.1. Patients’ qualitative results  
I provide an overview of the observations from the DOTS procedure in the clinic and 
highlight the specific skills learnt during my involvement with the clinic staff. 
 
4.9.1.1. Observations from DOTS procedure  
When the patients take their medication, the DOTS supporter sat directly opposite the 
patient to ensure that TB medications were taken by them e.g. making sure they have 
swallowed properly by talking to them. For those patients unable to attend the clinic 
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because of employment duties their TB medication was given to the employer provided 
that a patient consent was established.  
 
It was observed that elderly patients crush their tablets because they were unable to 
swallow them whole. This act was however not done under the direct personal 
supervision of the nurse or DOTS supporter and the pharmaceutical implication was that 
this could lead to poor bioavailability of the drug. In addition, the crushing of tablets 
should only be done by an authorized HCP such as a clinic nurse. Furthermore, the 
bioavailability of enteric coated tablets such as Rifafour® is reduced when crushed 
because the active ingredients are degraded by gastric acid (Decloedt E., and Maartens G, 
2009).  
 
The 7-day TB regimen which includes Saturday and Sunday weekend supply was given 
to TB patients and this meant that patients were entrusted with taking their medications 
on their own. The main pharmacotherapeutic concerns relating to this are firstly possible 
non-adherence and secondly personal social habits such as alcohol consumption over the 
weekend which could negatively affect the therapeutic outcome of their treatment.  
 
4.9.2. Quantitative results 
Quantitative data obtained from the patient questionnaires are tabulated in Table 4.2 
below. 
 
TABLE 4.2: RESULTS FROM BASELINE STUDY 
A. Patient background information Frequency 
( n= 12) 
Percentage 
% 
Gender 
Male 
Female 
 
4 
8 
 
 33,3  
 66.7   
Age range in years 
<20  
20- 29  
30- 39  
40-59  
>60  
 
1 
7 
1 
2 
1 
 
8.33 
58.3 
8.33 
16.7 
8.33 
Race 
Black   
White   
 
0 
0 
 
0 
0 
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Coloured  
Indian    
Other 
12 
0 
0 
100 
0 
0 
Home language 
English   
Afrikaans  
Xhosa   
Other 
 
0 
12 
0 
0 
 
0 
100 
0 
0 
Highest education 
None  
Primary level (<8)  
Secondary level (grade 8- 12)            
Tertiary level 
 
0 
3 
9 
0 
 
0 
25 
75
0 
Employment status 
Employed               
Unemployed              
Other 
 
1 
11 
0 
 
8.3
91.7 
0 
Residential status 
Urban              
Rural 
 
11 
1 
 
91.7 
8.3 
Living conditions 
House                
Informal settlement                 
Flat                 
Other 
 
10 
0 
2 
0 
 
83.3
0
16.7
0 
Socioeconomic status 
Salary/wages             
Casual handouts             
UIF(unemployment insurance fund)               
Social services grant 
None                                                                     
 
1 
0 
0 
3 
8 
 
8.3 
0
0
25 
66.67 
B. Medical History 
Family member with TB               
Knowledge about TB infection 
Contagious              
Non-contagious                                                                                           
 
3 
 
10 
2 
 
25
 
83.3
16.7 
Duration with TB* 
<1 month                                                                                                     
2–3months                                                                                                  
3-4 months  
4-5 months  
 >5 months 
 
4 
4
2 
3 
2 
 
33.3 
33.3 
16.7 
25 
16.7 
                                                           
Patients with TB only 
With HIV                                                           
With diabetes 
 
9 
2 
1 
 
16.7 
75 
8.3 
C. Symptom History* 
Vomiting                                                           
Nausea                                                           
Increased appetite                                                             
Headache                                                             
Abdominal pain                                                             
Diarrhea                                                           
 
2 
3 
4 
3 
2 
1 
 
16.7 
25 
33.3 
25 
16.7 
8.3 
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Drowsiness                                                           
Muscle weakness                                                          
Decreased appetite                                                          
Other (back pain)                                                         
None 
3 
4 
2 
1 
1 
25 
33.3 
16.7 
8.3 
8.3 
Patient preference for an HCP regarding 
discomfort resulting from TB medication      
Doctor                                                             
Nurse                                                              
Pharmacist                                                             
Other 
 
 
3 
2 
0 
0 
      
 
25 
16.7 
0 
0 
Facility most consulted for TB care 
 
Clinic                                       
Hospital                                         
Pharmacy                                         
Other 
 
 
12 
0 
0 
0 
 
 
100 
0 
0 
0 
D. Drug Treatment                                         
TB drug readiness programme attendance 
Yes                                                                
No                                                                                            
 
 
0 
12
 
 
0 
100 
Opinions about duration of TB treatment 
Too long 
Fine 
Too short  
Other 
 
1 
11 
0 
0 
 
8.3 
91.7 
0 
0 
Knowledge about main function of TB tablet 
Yes                                                                                                                    
No                                                                                                                       
 
12
0
 
100
0
Opinions about the amount of TB tablets 
administered 
Too big 
Fine 
Too much 
Other 
 
 
5 
6 
1 
0 
 
 
41.7 
50 
8.3 
0 
Other medications taken by TB patients 
ARV’s  
Traditional medicine  
Other (antidiabetics) 
 
2 
1 
2 
 
40 
20 
40 
Number of patients collecting TB medication 
monthly 
Yes  
No 
 
 
0 
12 
 
 
0 
100 
Patients whose TB treatment supervised 
Yes  
No 
Duration of treatment 
6 months 
8 months 
9 months 
 
12 
0 
 
9 
2 
1 
 
100 
0 
 
75 
16.7 
8.3 
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E. Lifestyle* 
Smokes cigarettes                                                                   
Consumes alcohol                                                                   
3 or more course meal 
 
6 
3 
11 
 
50 
25 
91.7 
Barriers to follow up appointment 
No transport                                                                  
No money                                                                  
Work                                                                   
Forgetfulness                                                                    
Other                                                                    
None  
 
1 
0 
1 
1 
3 
6 
 
8.3 
0 
8.3 
8.3 
25 
50 
F. Counselling* 
HCP seen as information source 
Nurse                                      
Doctor                                                    
Pharmacist                                                    
Support group                                                    
Other 
 
 
9 
3 
0 
1 
1 
 
 
75 
25 
0 
8.3 
8.3 
Patients preference for HCP to 
Nurse 
Doctor 
Pharmacist  
Other 
 
8 
3 
0 
0 
 
72.7 
27.3 
0 
0 
Type of information preferred by patients 
Verbal 
Reading material 
Both 
 
 
5 
0 
7 
 
 
41.7 
0 
58.3 
Perceived involvement of pharmacist in TB 
Positive (means any opinion other than that of a 
drug supplier) 
Drug related information   
Negative(means opinions that is drug-related) 
Psycho-social information 
 
 
4 
 
 
7 
 
 
36.4 
 
 
63.6 
 
* Patients could indicate more than one answer and therefore total percentages may 
exceed 100%. 
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4.10. Graphical representation of baseline results 
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Figure 4.2: Gender distribution of patients 
 
A total of 12 patients were approached to participate in the baseline study; none were lost 
to follow-up. Therefore, all 12 patients were recruited and interviewed, and their gender 
distribution is shown in the figure 4.2 above. Clearly there are more females (66.7%) than 
males (33.3%). This finding could imply that the burden of TB is more likely among 
females (HSRC report, 2005, see chapter 1, section 2.2). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Type of patient TB treatment case 
 
Figure 4.3 shows that nine of the 12 (75%) patients interviewed in this baseline study 
were newly diagnosed TB treatment cases and the remaining three (25%) were 
retreatment cases. Newly diagnosed TB patients receive treatment for a duration of 6 
months while for retreatment patients, the treatment is usually 8-9 months (PALSA Plus 
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manual, 2007). Findings from above indicate that the incidence rate of TB in this 
community seems to be on the increase as three-quarters of the patients have been newly 
infected. With the rising number of newly infected patients, pharmacists, other HCPs and 
students will need to keep abreast of screening, monitoring, treatment protocols and 
referral systems of HIV and its opportunistic infections (Syed IA et al, 2009).  
 
Rifafour® and other drugs
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Figure 4.4: Number of patients taking Rifafour® with other drugs 
 
Four of the 12 TB patients were taking Rifafour® with their antidiabetics (n=2) and 
ARV’s (n=2). One patient each took cough medication and Vitamin B.Complex. As 
mentioned in the previous chapter, Ravensmead CHC is predominantly a TB clinic with 
very few HIV-positive patients and may have been the reason why only one-quarter of 
the patients took other medications (ARV, antidiabetics and cough medication) with their 
anti-TB drugs. The pharmacist’s responsibility to check for potential drug-drug 
interactions is crucial to ensure optimal therapeutic outcomes.  
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Figure 4.5: Common TB side effects experienced by patients 
 
Four patients experienced nausea, three patients experienced increased appetite, 
drowsiness, and headache, two patients experienced abdominal pain, and five patients 
each experienced decreased appetite, vomiting, nausea and vomiting, diarrhea and back 
pain. The onset of side-effects resulting from complex drug therapy is likely to deter 
patients from adhering to their prescribed regimen (Chesney MA et al, 2000) which 
impacts negatively on health outcomes. Healthcare professionals including pharmacists 
are required to closely monitor side-effects and take appropriate actions where necessary.  
 
4.11. HCP results 
Since the clinic nurse and the DOTS supporter were the only staff alongside which I 
worked with, it was essential to ascertain their views and opinions about the pharmacist’s 
involvement in TB and HIV management. This was achieved when they  
completed the survey (Appendix B). 
 
TABLE 4.3: Comparative survey responses between DOTS supporter and clinic     
nurse 
 
 DOTS 
supporter(n=1) 
Clinic nurse(n=1) 
1. Gender Female Female 
2. Age 40-59 < 60 
3. Qualification DOTS training Basic nursing Diploma 
4. TB experience ( years) 3-5  1-2  
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5. Use of clinic card to monitor 
TB care 
Yes, only TB 
symptoms but not 
adherence to 
treatment. 
Yes, both TB symptoms 
and adherence to 
treatment. 
6. Provision of drug 
information to TB patients 
None Yes, provides information 
on side effects and 
frequency of drug 
administration. 
7. Frequency in promoting 
HIV testing 
Always Always 
9. Onset of TB counselling TB suspects TB suspects, new and re-
treatment patients. 
10. Response to side effects and 
drug interactions 
Refer to doctor. Refer to doctor. 
11. View on which HCP is most 
equipped to deal with drug 
interactions and side effects 
and a possible reason 
Doctor, extensive 
clinical experience. 
Doctor, extensive clinical 
experience. 
12. View on a trained 
pharmacist offering TB clinical 
services other than of a drug 
supplier 
Yes No, pharmacists should 
place more emphasis on 
drug interactions. 
13. Ability to manage TB 
patients who suffer from co-
morbid conditions and receive 
treatment that illicit potential 
drug interactions 
Not well managed. Not well managed. 
14. Would you support a 
complementary role for 
pharmacists in a clinic- based 
TB programme? 
 
 
Yes Yes 
HCP comments  Stressed that time maybe 
limited in such a setting to 
interact with pharmacists 
due to her workload. 
 
 
It seems evident that both the DOTS supporter and the clinic nurse perceived the 
pharmacist as a peripheral member of the primary healthcare team. Even though they 
believed that the pharmacists’ role was related to addressing dug-related risks, both the 
DOTS supporter and the clinic nurse supported a complementary role for pharmacists 
engaging in a clinic-based TB programme.   
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4.12. Summary of findings from baseline study 
 
There was an unequal proportion of male (33.33%) to female (66.67%) patients. Even 
though three-quarters (75%) of the patients had secondary level education almost all 
(92%) were unemployed. Three quarters (75%) of the patients were newly treated for the 
first time and were prescribed Regimen 1 which is specifically for adult patients. A 
quarter (25%) of the patients were being re-treated for TB. If pharmacists could screen 
patients and trace contacts for TB symptoms, this could help prevent the spread of the 
infection and subsequently lower the incidence rates.  
 
None of the patients had attended a TB/HIV drug readiness-training programme and they 
were not familiar with its importance. Even though almost all (92%) of the patients 
indicated that the duration of TB treatment was fine, a few (8.3%) believed that it was too 
long. All the patients (100%) claimed to understand the TB information given to them by 
the clinic nurse and felt that they were aware of the functions of the tablets however, 16% 
of these patients did not know the names of their anti-TB drugs. Most patients (83%) 
seemed to identify TB treatment from at least one of two coloured tablets comprising the 
TB regimen namely Rifafour® and Vitamin B6. Half of the patients (50%) felt that the 
purple tablet (Rifafour®
 
) was too big to swallow. Even though all patients (100%) 
received supervised TB therapy, most of them (83%) claimed that they were actually 
comfortable being observed. Half of the patients (50%) smoked at least 1 cigarette stick 
per day and a quarter of them (25%) stated that they consumed alcohol while on TB 
treatment. With increasing TB caseload possibly due to HIV co-infection and increasing 
clinical workload in PHC, nurse-led TB care can easily be supported by trained 
pharmacists.   
A trained pharmacist who has extensive knowledge in pharmacotherapy and drug 
formulation could work alongside a clinic nurse and promote treatment adherence. By 
alerting patients to the actions of drug therapy, highlight the factors that lead to drug 
resistance, and offer tailored advice to pharmaceutical formulation needs, it would lessen 
the load expected of clinical nurse practitioners. In view of the extensive 
pharmacotherapeutic training, pharmacists are under-utilized in TB management. Their 
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peripheral role contributes minimally to addressing the social and economic barriers 
affecting treatment adherence.  Therefore an expanded role towards a clinic-based TB 
care programme could optimize care provision. 
 
Survey responses from the DOTS supporter and clinic nurse underpin the need for 
pharmacotherapeutic and pharmacokinetic expertise from a clinic-based pharmacist, who 
can complement the role of a TB clinic nursing staff. Findings from the baseline study 
demonstrate the need for the involvement of a pharmacist in TB and HIV management. 
Of particular interest was the answer to question 5, where both the clinic nurse and DOTS 
supporter answered “Yes” to using the TB clinic record card to monitor patients. Based 
on this positive response, the researcher subsequently adapted and modified the existing 
clinic record card (Appendix H) into a clinic-based intervention tool for potential use by 
trained pharmacists. The effectiveness of the clinic-based intervention tool was 
subsequently tested at Delft South ARV clinic and Elsies River TB clinic (chapter 5). In 
preparation for this, I modified the existing baseline questionnaires for implementation at 
Delft South ARV and Elsies River clinics.  
 
 
Modifications to baseline questionnaires (Appendix A and B) for study at Delft South and 
Elsies River clinics.  
 
A few modifications were made to the original baseline questionnaires (Appendix A and 
B) for the study at Delft South ARV and Elsies River clinics. From Appendix A, question 
1b was made a closed ended question i.e. Yes or No response to obtain definitive 
answers. Question 3 became number 2 and in addition was also made a closed-ended 
question. Question 4 became question 3 and vice versa. Question 15 was specified to 
include open-ended questions. Questions’ having “Other” as an option was also specified. 
From Appendix B (HCP questionnaires), question 6 was made a closed ended question 
by providing options. 
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4.14. Conclusion 
 
It is clear that TB management offered by nurses is suboptimal with regard to addressing 
the pharmacotherapeutic needs of patients. The presence of a trained pharmacist in a 
clinic setting could promote better understanding of TB treatment, address key aspects of 
pharmaceutical formulation and devise adherence strategies. A trained pharmacist could 
work alongside nursing staff to provide both drug and non-drug related treatment 
strategies, access patient readiness to start ARV’s and be part of the decision making 
team in the clinical management of TB and HIV. 
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CHAPTER 5: DESIGN, IMPLEMENTATION OF INTERVENTION TOOL AND 
ASSESSMENT OF FINAL YEAR PHARMACY STUDENTS.  
 
In order to meet the primary objective of this study and following findings from the 
baseline study, this chapter discusses the design of a clinic-based intervention tool and its 
implementation at two clinics, namely the Delft South ARV clinic and Elsies River TB 
clinic. The intervention tool was designed with the intention that it could be used by 
trained pharmacists. However, along with severe staff shortage, high patient overload and 
an array of administrative commitments the recruitment of practicing pharmacists in this 
exploratory study was not possible. The researcher’s training in PALSA Plus served as a 
common platform to engage with the staff on clinical activities with minimum disruption. 
Both qualitative data and quantitative data were collected to obtain insight that would be 
both holistic and authentic during implementation of the intervention tool at the two 
clinics.  
 
Qualitative data was collected from the researcher’s observations to obtain an in-depth 
account from interactions and experiences with clinic staff. The researcher diarized each 
day’s experiences which included amongst others patient-HCP interaction and staff 
interactions. These notes were subsequently transcribed in detail, categorized and 
common themes were identified. Quantitative data was obtained from the researcher’s 
use of the clinic-based patient data.  
 
In order to meet the secondary objective of this study, this chapter describes the 
assessment administered to final year pharmacy students (2009), at UWC School of 
Pharmacy. The objective was to ascertain if a clinic-based TB/HIV management 
programme was needed in undergraduate pharmacy training. It provides the rationale for 
the assessment of students’ knowledge, perceptions of TB/HIV management and 
concludes with a description of the clinic-based training that the researcher conducted 
with a group consisting of seven final year pharmacy students. 
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5.1. Implementation of the clinic-based intervention phase 
Following findings from the baseline study (chapter 4), the patient and HCP 
questionnaires were subsequently modified for their implementation at the intervention 
clinics. The intervention was implemented over a period of 3 months at Delft South and 1 
month at Elsies River clinics from July 2008 to October 2008.   
 
5.2. Delft South Staff members 
I describe the duties of the staff namely the ARV nurse, adherence counsellor, and patient 
advocate whom I worked with at Delft South ARV clinic. The description of their duties 
is largely based on my personal observations during my interactions as a participant 
observer. 
 
5.2.1. ARV nurse/clinic nurse 
The ARV nurse also known as the clinic nurse at this clinic was responsible for a number 
of HIV related duties such as dispensing ARV’s to patients, screening HIV-positive 
patients to determine whether they were eligible for ARV treatment, monitoring patient 
adherence, drawing blood for CD4 count, and providing patients having HIV/AIDS with 
health education. Other duties include seeing HIV-positive patients on a weekly basis in 
the first month of their treatment and once a month after successful initiation of ART. 
 
5.2.2. Adherence counsellor 
The adherence counsellor at this clinic was a female in her middle forties. She was 
responsible for the drug-readiness training programme otherwise described as the clinical 
assessment of patients for ART initiation. The programme runs for 3 weeks at Delft 
South ARV clinic as opposed to the 4 weeks recommended by the Free State Department 
of Health and is divided into three sessions. Session one covers general HIV education 
and healthy living. Session two covers ARV’s, and the third session deals with adherence 
planning. The counsellor uses a clinic form as a guide (see Appendix F, number 6) to 
ascertain patient adherence information. The adherence counsellor works closely with the 
patient advocate (PA) to monitor adherence. In some instances patients were “fast-
tracked “which meant they were started on ART within 2 weeks as opposed to 3 weeks 
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because their CD4 count was considered to be very low (i.e. below 50 and already on 
anti-TB medications). The counsellor ensures that continual HIV education is provided 
even after initiation of ART. 
 
5.2.3. Patient advocate (PA) 
A total of ten PA’s offer their services at the clinic, with each assigned to at least one 
patient as a treatment supporter. Patients who had successfully completed counselling 
with the adherence counsellor were deemed clinically ready to start ARVs. The PA’s 
usually visit patients at their homes to assess adherence to treatment and factors that 
prevent them from taking their medication such as lack of food, lack of a grant e.t.c. In 
addition, PA’s assist the clinic nurse when undertaking pill counts to verify patient 
adherence to prescribed treatment and they also supervise support group meetings which 
is held every Friday at the clinic. 
 
5.3. Elsies River staff members 
Table 5.1 (below) outlines a brief description of the roles and responsibilities of the 
various staff members who render services mostly to TB patients and some HIV positive 
patients at Elsies River clinic. 
 
Table 5.1: Summary of staff roles and responsibilities at Elsies River clinic.  
Staff Roles and responsibilities  
1. Clinic nurse 
(located within the 
TB-room) 
Completes prescriptions, checks VCTs and family planning done 
on all new patients, and writes out medication packets for 
monthly DOTS supporter treatments. 
2. VCT counsellor Test all TB suspects, gives patient appointment for care clinic if 
Retroviral Disease (RVD) positive. 
3. HOPE(HIV 
outreach program 
and education) 
CHW 
 
Assists with DOTS, TB defaulters, advices health promotion 
daily in TB waiting rooms for 10 minutes, and checks folder of 
TB patients to see if VCT has been done. 
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4. Clinic DOTS 
supporter 
Assists and observes patients taking medications in clinic, weighs 
all TB patients’ monthly, advices on health promotion, interacts 
with patients, and checks folders for sputum reminders. 
 
The various roles and responsibilities of each staff member at the clinic clearly underpins 
the ARV roll out at primary healthcare facilities. In their engagement with each other, it 
is envisaged that care provision should be integrated. However, the pharmacist seems 
peripheral and disconnected with the rest of the clinic staff. In a TB/HIV clinic a trained 
pharmacist would be pivotal to engage directly with the clinic staff and patients to 
monitor treatment outcomes. 
 
Findings from the baseline study prompted the design of a tuberculosis clinic record card 
for potential use by trained pharmacists.  
 
5.4. Design of intervention tool: Tuberculosis clinic record card 
 
The intervention tool (see Appendix G) entitled “Tuberculosis clinic record card” was 
intended for use by trained pharmacists. Its design and layout was adapted from the TB 
patient record card routinely used by clinic nurses (see Appendix H: GW 20/12, 2002). 
The tool was blue as this was one of the universally acceptable colours for respiratory 
disease. The tool was divided into sections A-J but also had some uncategorized 
information such as TB record card number, clinic file number, clinic name, registration 
date with pharmacist, the date TB treatment started and expected date of treatment 
completion. Section A focused on the patient facility status and helped to collect data on 
patient details, Section B focused on patient TB treatment, Section C categorized TB 
according to the international code for disease (ICD-10), Section D was for noting patient 
sputum results because it aided the clinic nurse with diagnosis and screening, Section E 
was intended to record the patients TB treatment supervisor(s) and their details, Section F 
focused on adult regimen and dosages, Section G was used to assess patient adherence 
status, Section H was used to collect data on specific TB side effects, Section I focused 
on drug interactions and lastly Section J was reserved for patient treatment outcomes.  A 
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graphic designer used Corel Draw to enhance the layout of the card. The main headings 
for each section were bold type, Times New Roman font was used with font size 14. The 
remaining text had the same font, but the font size was reduced to 12.  
 
5.5. Rationale for the clinic record card 
 
I discuss the rationale for the questions pertaining to each section (sections A-G) of the 
clinic-based record card. I also draw on the main aims for each and its applicability for 
use by a trained pharmacist. 
 
Section A 
 
This section was aimed at collecting patient data such as their demographic profile 
namely age, weight, race, and sex respectively. Non-demographic data collected from 
this section included the diagnosis of the patient, other concurrent conditions the patient 
had, duration of the other condition(s) and finally the type of TB case they were being 
treated for. The questions pertaining to the patient facility status were used to ascertain 
whether the patient was newly listed to the facility or if s/he had been newly transferred 
to the clinic for the first time. All of these patient details were required for tracking 
purposes i.e. name and surnames helped to track patients for follow-up care and to check 
the patient’s progress during the post-intervention phase.  
 
Section B  
This section was themed “TB patient category” and aimed to categorize the type of TB 
treatment case each patient received from the clinic. This was necessary as there are 
different types of retreatment cases encountered clinically for example some patients had 
previously received TB treatment and defaulted whilst some where new case patients. 
The retreatment patients were sub-categorized into retreatment after failure (RF), 
retreatment after previous cure (RC), retreatment after interruption (RI), and retreatment 
after previous completion (RAC).  
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Section C 
Questions from this section were based on the ICD-10 code mentioned above (see 5.4). 
The selected codes and their clinical definitions namely A16.2, A16.5, A16.7 and A18.8 
(outlined in table 5.2) represented cases of TB that were frequently encountered in 
practice.  
 
Table 5.2: ICD-10 code for different types of TB 
ICD-10 code Definition 
A16.2 According to the ICD-10 code, this is defined as TB of the lung without 
bacteriological or histological confirmation. It includes TB of the lungs, 
bronchiectasis, pneumonia, fibrosis of the lung, and pneumothorax.  
A16.5 This is TB of the pleura, TB emphyema and unspecified respiratory TB. 
A16.7 This is primary respiratory TB without mention of bacteriological or 
histological confirmation that combines hilar/mediastinal 
lymphadenopathy. It is also a combination of a small opacity in the lung, 
3-10mm in diameter.  
A18.8 This is TB of other organs such as peripheral lymphadenopathy, skin, 
eye, ear etc.  
Section D was required to record the results obtained from diagnostic and screening tests 
that were conducted with sputum results from TB patients. This was tabulated and had 
three sub-headings namely; pre-treatment, end of intensive phase and culture results 
respectively. Under the pre-treatment and end of intensive phases the smear dates and 
smear result(s) were noted. The culturing of sputum is done because TB cultures are 
more sensitive than smear microscopy in detecting TB among patients with TB 
symptoms and signs. These patients are considered as nonconverters and must receive the 
retreatment regimen. The DOTS supporter usually collects the sputum for culturing in the 
laboratory (Ndjeka N et al, 2008).  
From the baseline results, I found that all the patients surveyed were supervised by a 
treatment supervisor (see chapter 4, table 4.2) and this prompted the theme for section E.  
Six possible treatment supervisors that were identified were the patient’s relative, a clinic 
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nurse, teacher, DOTS supporter, pharmacist and other healthcare provider(s). Information 
pertaining to the treatment supervisor(s) name, address, and telephone number was 
needed to monitor the patient treatment progress.  
 
Section F investigated the appropriateness of the prescribed pharmaceutical regimen and 
its dosages. Enquiry was made into the type of adult TB regimen the patient was 
receiving and its initiation date. This section was subdivided into the intensive phase and 
the continuation phase because TB treatment is received over a 6-month period divided 
into two phases namely, the intensive and continuous phases. 
 
Intensive phase of TB treatment 
Information on the number of drugs, their dose, strength and frequency of drug 
administration to patients are required to check adherence and treatment outcomes. A 
fixed combination drug known as Rifafour® is given in clinics because it reduces pill 
burden. Rifafour® comprises four of the first-line anti-TB drugs used for the treatment of 
TB as a single pill (see chapter 2, section 2. 6). Other drugs taken concurrently during 
this phase include Pyridoxine (Vitamin B6), Vitamin B complex and Cotrimoxazole 
(Bactrim®) and for the purpose of this study, other drugs would include Antiretrovirals 
(ARV’s). The DOTS supporter who monitors the patient’s daily intake of TB 
medications records this activity in the tabular template (see Appendix G, section I, 
number 1). 
 
The DOTS supporter is guided by certain symbols when supervising the patient’s drug 
treatment. The DOTS supporter usually notes the name of the drug administered on the 
particular day and uses either one of the following symbols “√”, “X”, “O”, and “ -’’as 
deemed appropriate. The symbol ‘’√’’ means that medication has been taken under the 
supervision at the clinic, the symbol ‘’X’’ means that the patient did not collect his/her 
medication, the symbol ‘’O’’ means that the patient did not have to collect the medication 
because they were given a weekend package. The symbol ‘’-‘’ means that medication 
was collected for self-administration or supervision elsewhere (National Tuberculosis 
Control programme patient clinic/hospital card (GW 20/12, 2002).  
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In this study symbols (“X”, “O”, and “-“) were used in noting the supervision of the 
patient’s treatment. In addition, other symbols were added namely “N” and “P” where 
“N” denoted nurses and “P” denoted pharmacists.  If the patient took the medication 
under the strict supervision of a nurse, the symbol ‘’N’’ was noted in the card and if the 
medication was taken under the strict supervision of a pharmacist, “P” was noted in the 
card. A calendar depicting each day of the month was included under this section for 
tracking follow-up visits. 
 
Continuation phase of TB treatment 
The drugs used for the continuation phase were different from those used in the intensive 
phase. Therefore the drug RHZE in the first column was replaced with HR, the 
combination RHZ replaced with H, and S replaced with E (see Appendix G). The layout 
for capturing drug information (dose, number of tablets given, strength and frequency of 
dosing) for the TB continuation phase was similar to the intensive phase. A table 
resembling a calendar depicting each day of a month was also included under this 
section.  
 
Assessing patient adherence to treatment at the intervention clinics 
The terms adherence and compliance are defined because they have different meanings. 
The term adherence focuses on the degree to which a patient follows a treatment regimen 
while compliance has psychologically fewer benefits and can be perceived as an 
instruction where the patient is a passive recipient of the treatment (HIV/AIDS clinical 
management for pharmacist students, 2006).  
 
At Delft South ARV clinic, adherence is measured at the end of the month from pill 
counts and compliance diaries. The patient advocate determines adherence by counting 
the number of tablets that are left over in the pill container.  Compliance is measured 
from a patient’s medication diary (see Appendix I). The patient is required to record each 
dose taken for the day in the medication diary. The accurate completion of the diary rests 
solely with the patient’s level of motivation and honesty. The medication diary is written 
in several languages (isiXhosa, Afrikaans or English) to accommodate the patient’s 
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preference for example an isiXhosa medication diary will not be given to an Afrikaans 
speaking patient and vice versa.  
 
Section G assessed the patient’s adherence status according to the remaining number of 
pills leftover after a month’s treatment and this figure is expressed as a percentage of the 
total number of tablets that was dispensed at the beginning of the month.  For example, if 
there are no tablets left over, then the patient is regarded as 100% adherent.  The 
adherence status was categorized as either “bad”, “good” or “excellent” depending on the 
level of adherence that the patient could achieve. The patient’s adherence was considered 
“bad” when more than 2 pills were leftover, if 1-2 pills were leftover then their adherence 
was considered “good”, and “excellent” indicated that all pills were taken as prescribed. 
Questions in this section also ascertained how patients took their medications with regard 
to timing and any discomfort(s) they might have experienced that prevented them from 
taking their medications.  
 
Section H aided in collecting data on specific side effects such as peripheral neuropathy 
due to TB therapy, that the patient might have experienced. In addition their response in 
dealing with the side effect was noted.  Four options were provided namely; stopping of 
their current treatment, continuing with treatment despite the discomfort, delaying taking 
their treatment or other potential responses. Patients were also expected to note their 
preferred HCP that they had consulted with when such side effects were experienced. 
HCP’s that were listed included a nurse, pharmacist, doctor, traditional healer or any 
other person.  
 
Section I explored the common drug interactions between anti-TB drugs and ARV’s. 
Drug interactions of note occur between Rifampicin and ARV’s such as Kaletra® and the 
NNRTI's namely Efavirenz and Nevirepine. Some side effects arising from individual 
anti-TB drugs in co-infected patients were also outlined here. An example of such side 
effect was peripheral neuropathy caused by isoniazid.  
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Patients’ treatment outcomes such as drug interactions, contraindications, side effects, 
adverse effects were also recorded. For example, if patients suffered from rare conditions 
such as Immune reconstitution inflammatory syndrome (IRIS) then their treatment 
outcome will be recorded as adverse effects/reaction under this section.  
 
5.6. Applicability of tool for potential use by trained pharmacists  
 
The tool was designed with the intention to guide trained pharmacists in the clinic-based 
management of patients co-infected with TB and HIV. It was envisaged that this tool 
would enable pharmacists work directly with a clinic nurse, TB doctor, adherence 
counsellor and patient advocate in optimizing TB/HIV management. The tool would 
enable the ARV pharmacist monitor patients during their intensive and continuation 
phases of TB treatment. Of even greater importance is that during these TB treatment 
phases, patients may also be taking ARV’s concurrently. It is therefore envisaged that 
such trained pharmacists will be in the ideal position to make timeous clinic-based 
interventions to prevent potential harmful drug interactions.   
 
Following the clinic-based knowledge which I had attained from the PALSA Plus 
training (chapter 4, section 4.1), and my skills development in the TB and HIV clinics (4 
months) enabled me to design the intervention tool. Furthermore, I was able to form a 
solid foundation and in-depth insight into routine clinic procedures and protocols which 
served to achieve the primary aim of my study. Both the knowledge and first-hand 
exposure had equipped me adequately to engage in TB/HIV clinic-based duties and care 
provision which prepared me to undertake the secondary objective of this study (Phase 
II). 
 
The secondary objective of this study, aimed to explore if a clinic-based TB/HIV training 
was needed in undergraduate pharmacy training.  Final year UWC pharmacy students 
were the target group as they were familiar with the theoretical concepts on most 
infectious diseases (Pharmacology module 417, 2009) and were exposed to clinical 
rotations at public-sector healthcare facilities. Since the class lectures on the 
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pathophysiological and pharmacological concepts of TB and HIV were already 
conducted. It was envisaged that familiarity with these topics would enable them to 
determine if a clinic-based TB/HIV training was needed to supplement their training. 
Student assessments were pre-arranged with the Pharmacotherapy course co-coordinator, 
a senior academic staff member from the Discipline of Pharmacology, School of 
Pharmacy at UWC.  
 
Part 1: rationale for assessment questions 
 
Following the PALSA Plus training I had received from the district TB coordinator 
(chapter 4, section 4.1). I was conversant with the TB and HIV management protocol 
followed in the clinic. I therefore assessed the current final year pharmacy students at 
UWC on their TB and HIV knowledge.  Their perceptions about the potential role for 
pharmacists in TB and HIV management were also explored. In addition, my first hand 
clinic exposure at the two intervention clinics gave me the insight, practical knowledge 
and skills required for routine procedures at the clinic. The assessment was divided into 
two parts. The first part was used to collect quantitative data whilst the second part was 
not allocated any marks but was used to assess student’s knowledge and perceptions on 
the clinical management of TB and HIV. Overall, my experiences acquired equipped me 
with the skills to assess and train final year pharmacy students. Consequently, student’s 
assessment was based on the experiences I had acquired during my clinic visits. The 
student’s assessment had 23 questions in total with part one having 19 questions and part 
two having 4 questions.  
 
The layout of the assessment were as follows: student’s basic knowledge of TB 
(questions 1 to 7), their drug treatment knowledge (questions 8 to 11), and their HIV drug 
knowledge (questions 15 to 19). A typical clinical scenario that I personally encountered 
on numerous occasions at Delft South ARV clinic (see Appendix O, questions 19a to 
19d) was included to test the student’s knowledge in the management of co-morbid 
conditions such as TB and HIV, assess their application of theoretical knowledge 
acquired from class lectures.  
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Part 2: questionnaire to ascertain student views and perceptions  
This part of the student’s assessment was in the form of a questionnaire (questions 21 to 
23) that explored the views and perceptions of each student for a clinic-based training and 
the potential role of final year student in TB and HIV management. An enquiry was also 
made into their views of a proposed undergraduate clinic-based TB/HIV management 
programme to supplement their class lectures.  
 
5.7. Introduction of a clinic-based training for UWC final year pharmacy students 
 
The researcher conducted the training with seven final year students (chapter 3, section 
3.4.1) on the 9th
 
 of June, 2009. The researcher designed an outline of the training session 
and handed a copy to each student. The training session was formal, yet interactive thus 
allowing students the opportunity to ask questions at any point during the session. The 
students engaged in meaningful discussions that related to the case scenarios. This 
training session was interactive as my personal experiences were shared with the 
students. The training lasted for approximately 2 hours after which they were assessed. 
All seven students were asked to give their feedback on the training session. The contents 
of the training and training notes which were extracted from the PALSA Plus 2007 
edition are outlined below (see Appendix C).  
5.8. OUTLINE OF TRAINING CONDUCTED BY RESEARCHER FOR FINAL 
YEAR PHARMACY STUDENTS AT UWC  
 
Date: 9 JUNE 2009 
 
Contents:  
Importance of PALSA Plus approach to TB/HIV management 
Acronym 
Relationship with TB and HIV 
Target group 
Suspecting TB 
Distinctive Symptoms 
HIV and TB 
Diagnosing TB 
                   Criteria for new case suspect 
                   Criteria for retreatment case 
                   Treatment of TB (Sputum bacteriology) 
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      Treatment of HIV TB client 
                   CD4 count 
1.1.1 < 50 
1.1.2 50- 200 
1.1.3 200 and above 
Importance of Bactrim and Pyridoxine (Vitamin B6) 
TB treatment Wheel: its use in follow-up care 
Regimens for TB treatment  
Smear-positive client 
                    TB treatment table 
                    Anti-TB drugs 
                    Contra-Indications 
                    TB treatment phases 
                    Duration of TB Treatment phases 
      End of treatment 
                    TB cured 
                    TB completed 
                    TB failure 
ART first-line regimens for adult patients 
                     Regimen 1a  
                     Regimen 1b 
                     Contra-indications 
Second line ART regimen for adult patients 
                     Regimens 
                     Contra-indications 
     Counselling of TB/HIV patients (Drug Readiness Training) 
                     Session 1: Disclosure and positive living (Appendix J) 
                     Session 2: Basics of HIV, CD4 and Viral load (Appendix K) 
                     Session 3: Opportunistic infection’s, ARV Treatment Plan,  
                    Adherence (Appendix L) 
 
 
Healthcare professionals are required to optimize care for HIV/AIDS patients and 
minimize the rate of infection. This has compelled HCPs to scrutinize their practice for 
ways to keep up-to-date with current knowledge, treatment modifications of HIV and its 
infectious opportunistic infections such as TB (UNAIDS, 2006). It is therefore essential 
that pharmacy students are also up-to-date with the current clinical practice patterns in 
the management of TB and HIV provided at primary care clinics such as Delft South 
ARV clinic.  
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CHAPTER 6: RESULTS  
 
This chapter provides a narrative of results collected during the pre-intervention, intervention 
and post-intervention phases. The data was collected from the patients, HCP’s and UWC final 
year pharmacy students. The results are divided into two phases which are subdivided into three 
sections namely section one, section two and section three. Section one presents the results 
obtained from patients who attended Delft South ARV clinic. Section two presents the results 
from HCP’s at Delft South ARV and Elsies River clinics while section three presents the 
assessment results obtained from the UWC final year pharmacy students.  
 
Phase I study 
6.1. Section one: Pre-intervention results 
 
The aim of the pre-intervention study was to assess patient’s perception(s) towards the 
pharmacist and knowledge of their TB/HIV treatment. The main method of data collection was 
from questionnaires used during semi-structured interviews that lasted for approximately 10 
minutes per patient.  A total of 19 co-infected patients received the pre-intervention 
questionnaires. Knowledge of their clinical conditions and initial perception(s) towards the 
pharmacist was explored. A correlation between patient education and knowledge of their 
conditions seemed to be evident. 
 
I highlight the pertinent parameters relating to patient-centered care that were used to assess 
current practice patterns of TB/HIV management. These include enquiry into patient knowledge 
of their TB/HIV medication use, patient preference for a HCP, and their perceptions of the 
pharmacists’ role in treatment provision. 
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Table 6.1.1: Demographic profile of patients (n=19) at Delft South ARV clinic 
Gender  Frequency Percentage (%) 
Female  10 52.6 
Male  9 47.4 
Age  Frequency Percentage (%) 
20-29 5 26.3 
30-39 10 52.6 
40-49 4 21.1 
Education  Frequency Percentage (%) 
Primary  5 26.3 
Secondary   13 68.4 
Tertiary  1 5.3 
Home language  Frequency Percentage (%) 
Afrikaans 5 26.3 
English 1 5.3 
isiXhosa 12 63.2 
Others 1 5.3 
Race Frequency Percentage (%) 
Black 13 68.4 
Coloured 4 21.1 
White  2 10.5 
 
Results 
Just above half (52.6%) of the patients were females and the rest (47.4%) were males. Their age 
ranged from 20-49, with more than half (52.6%) of the population falling within the 30-39 age 
groups. Two-thirds (68.4%; 13) of them attained secondary (grade 8) education. In this study, 
most of the patients recruited were black South Africans (63.2%), mainly isiXhosa-speaking 
followed closely by the Afrikaans speaking patients (26.3 %; 5). Even though literature on Delft 
South community suggested that the dominant race were coloureds (75%) (Chapter 3, section 
3.1.2.), in this study, the dominant race for the pre-intervention phase were primarily black South 
Africans (68.4%), with only one-fifth (21.1% ) comprising Coloured patients. 
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Enquiry into patient knowledge of contracting TB 
 
Table 6.1.2: Patient knowledge of TB infectivity 
Is TB contagious?  Frequency Percentage (%) 
No  3 15.8 
Yes 16 64.2 
Are you aware of how you contracted TB?  Frequency Percentage (%) 
No  7 41.2 
Yes 10 58.8 
 
 
Almost two-thirds (64.2%) of the patients knew that TB was contagious. Although more than 
half (58.8%; 10) claimed they knew how they contracted TB, only one-quarter (30%; 3) 
attributed it to physical contact with infected sputum which may indicate poor understanding of 
information given to them by mainly nurses. Other mentioned reasons ranged from cold 
environment, cold beer, needles, and open wounds (70%; 7). Clearly many studies have 
indicated that patients with adequate knowledge of TB and its treatment are more likely to 
comply with their treatment than one with limited knowledge (Liam CK et al, 1999; Wandwalo 
ER, and Morkve O, 2000).  
 
Table 6.1.3: Enquiry into patient knowledge of TB/HIV tablets 
 
Knowledge of tablets  Frequency Percentage 
No  1 5.9 
Yes 16 94.1 
Colours of tablets 10 71.4 
Names of tablets 4 28.6 
Do you know what the tablets do?  Frequency Percentage 
No  1 6.7 
Yes 14 93.3 
 
 
For infectious diseases such as TB and HIV, it is crucial that co-infected TB/HIV patients 
understand how these infections are spread, so that adherence to their complex treatment 
regimens becomes meaningful. The correlation between patient education and knowledge of 
their condition was evident in the percentage of positive responses obtained. As mentioned 
earlier, more than two-thirds (68.4 %) of patients had received secondary education and 58.8% 
had knowledge of how TB was contracted (table 6.1.2). Furthermore, almost all (93.3%; 14) of 
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these patients knew what their tablets were meant to do, and knowledge of this requires some 
form of education that is beyond the primary level.  
 
Table 6.1.4: Enquiry into patient’s preference for a HCP(s) 
 
Preference with regards to patients TB/HIV discomfort  Frequency Percentage 
(%) 
Doctor 4 66.7 
Nurse 2 33.3 
Who gives TB information?  Frequency Percentage 
(%) 
Doctor  2 11.1 
Nurse  14 77.8 
Other  2 11.1 
Preferred HCP with regards to patients TB/HIV treatment  Frequency Percentage 
(%) 
Doctor  12 66.7 
Nurse  2 11.1 
Other  4 22.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: Patients preferred HCP regarding their TB/HIV treatment 
 
In this study, over three-quarters (77.8%) of the patients preferred to receive TB information 
from the clinic nurse, while two-thirds (66.7%) of these patients preferred the doctor to the clinic 
nurse when it came to their TB/HIV treatment in general. The doctor seemed the most favoured 
HCP, since patients preferred consulting them for any discomfort arising from TB/HIV 
treatment. Even though nurses are designated front-line care providers at ARV clinics, patient 
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preference for care from doctors seem a primary source. One possible reason could be that due to 
the large number of patients receiving care from nurse-driven clinics and increasing 
administrative load, the quality of care may be compromised.  
Supportive clinic-based services can also be offered by trained pharmacist who can address the 
pharmacotherapeutic needs of patients. The pharmacist’s role in addressing medicine related 
risks are cornerstone to primary healthcare service provision.  
 
Table 6.1.5: Enquiry into patient lifestyle  
 
Smoking  Frequency Percentage (%) 
No  13 72.2 
Yes  5 27.8 
Alcohol consumption Frequency Percentage (%) 
No  7 36.8 
Yes  12 63.2 
Access to 3-meals daily Frequency Percentage (%) 
No  3 15.8 
Yes  16 84.2 
 
Smoking prevalence among Black South Africans is lower than their Coloured and Indian 
counterparts. The prevalence of smoking among people with primary and secondary education 
was shown to be higher than those with tertiary education (Walbeek C, 2001). Almost two-thirds 
(63.2%) of the patients claimed that they consumed alcohol. This percentage is disturbing 
considering that alcohol increases the risk of hepatotoxicity and peripheral neuropathy in patients 
concurrently on TB treatment.  Furthermore, the risk of developing active TB disease is higher 
when tobacco smoking is combined with alcohol (Ramakant B, 2009). It has been shown that 
good nutrition is essential for the patient on ARVs because it helps to boost the immune system 
which contributes to an increase of their CD4 count (Prasad R, 2007). It was relieving to know 
that more than three-quarters (84.2%; 16) of the patients ate at least three square meals a day, 
lack of food is a major barrier to adherence (http://All About Antiretroviral treatment art.mht). 
Therefore, Healthcare professionals who treat patients with TB and HIV should encourage a 
healthy lifestyle which includes amongst others refrain from the use of tobacco, and the 
consumption of alcohol when taking their chronic medications (Goodman A, 2009).  
 
 
 
 
 
 
 83
Table 6.1.6: Enquiry into the potential role of the pharmacist in patient treatment 
provision 
 
Can the pharmacist help 
with treatment?  
Frequency Percentage 
No  7 36.8 
Yes 12 63.2 
 
Almost two-thirds (63.2%; 12) of the patients believed that pharmacists assisted with their   
treatment provision without direct patient engagement. This implies that pharmacists currently 
offer a product-centered care rather than a patient-centered one, a finding that is fully endorsed 
by Williams (2006). Along with their technical skills, pharmacists are expected to develop a 
“covenantal relationship” which is one based on moral values with their patients. This role is 
however non-existent among pharmacists in primary healthcare facilities. If pharmacists need to 
be recognized as competent healthcare providers in the primary healthcare team, a clinic-based 
role might offer a feasible option.  
 
Section two: HCP’s results  
 
The Delft South ARV clinic staff completed self-administered questionnaires and their responses  
are tabulated below. 
 
Table 6.1.7: Comparative responses from ARV nurse, adherence counsellor and TB doctor 
at Delft South ARV clinic 
 
 ARV nurse  Adherence 
counsellor 
TB/ARV doctor 
Gender Male  Female Female 
Age range 40-59 40-59 30-39 
Qualification Basic nursing 
degree 
No answer Medicine degree 
TB experience ( 
years) 
6-10 years 3-5 years 1-2 years 
 
Use of clinic card to 
monitor TB care 
Yes  Yes  Yes 
Provision of drug 
information to TB 
patients 
Adverse effects No answer Advice on drug 
interaction. 
Frequency in 
promoting HIV 
testing 
Sometimes Always Always 
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Onset of TB 
counselling 
All patients All patients New patients 
Response to side 
effects and drug 
interactions 
Doctor Doctor  TB Doctor  
View on which 
HCP is most 
equipped to deal 
with drug 
interactions and 
side effects and a 
possible reason 
 
 Nurse Doctor Doctor  
View on a trained 
pharmacist offering 
TB clinical services 
other than of a 
drug supplier 
No answer No answer Pharmacists should 
consult on side effects 
and contra-indication. 
Ability to manage 
TB patients who 
suffer from co-
morbid conditions 
and receive 
treatment that 
elicits potential 
drug interactions 
No answer No answer Frequent monitoring, 
explaining to patients 
when to come back, give 
them clinic phone 
number. 
 
 
 
 
Would you support 
a complementary 
role for 
pharmacists in a 
clinic- based TB 
programme? 
Yes No answer Yes 
HCP comments Pharmacists must 
have a 
complementary role. 
No answer None 
 
The experience of the ARV nurse in TB care was approximately twice (6-10 years) the 
individual experience of both the adherence counsellor and TB doctor (3-5 years each). 
Interestingly, all HCP’s answered “Yes” to using the routine clinic card (GW 20/12, 2002) to 
monitor TB care but none of the HCP’s felt pharmacists were well equipped to deal with drug 
interactions and side effects. Although all three HCP’s use the PALSA Plus approach,  the ARV 
nurse only promoted HIV testing to some TB patients, an act which is contrary to the PALSA 
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plus approach of care which clearly states that HIV testing should be promoted to all TB patients 
(see PALSA Plus notes, 2007 edition, page 6).   
 
Findings from above, coincides well with the Van der Walt’s study (2006) where general 
practitioners did not support an expanded role for pharmacists because they felt pharmacists had 
limited knowledge (Van der Walt E, and Summers S, 2006).  
 
In comparison to the baseline study (chapter 4), HCP’s views on the most equipped to deal with 
drug interactions and side effects did not change as they all felt that the doctor was the HCP most 
equipped to offer these services. The doctor supported the notion that properly trained 
pharmacists can offer TB/HIV clinical services but on condition that they consult for treatment 
outcomes such as side effects, and contraindications.  
 
I observed during the duration of my stay at this clinic that the ARV pharmacist was mostly 
always situated in the clinic pharmacy and did not interact directly with the other HCP’s. It is 
envisaged that lack of constant presence by the ARV pharmacist contributed negatively to the 
views of other HCP’s on the role of the pharmacist in TB/HIV management and the poor initial 
perceptions from the patients. The Health Systems Trust (HST) reported that  there was still a 
need for more healthcare professionals, particularly pharmacists, to make the intended nurse-
driven, clinic-based approach work properly (SOUTH AFRICA: Nurses to fill gaps, 2005). 
 
6.2. Intervention phase results (n=98) 
 
The aim of the study was to assess the effectiveness of the intervention (a trained researcher 
using specially designed clinic record card) on patients TB/HIV treatment. The researcher used 
the clinic record card for 4 months (July 2008 to October, 2008). A total of 98 co-infected 
patients attending the Delft South ARV (n=72) and Elsies River TB clinics (n=26) received the 
intervention. I discuss the clinical data which are relevant to testing the effectiveness of the 
intervention in relation to TB/HIV care provision and patient health outcomes.  
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Table 6.2.1: Age distribution of patients 
Age range Frequency Percentage (%) 
0-29 22 23 
30-39   49 53 
40-49  17 18 
50-59 4 4 
60-69 1 1.1 
Total  92 100 
 
 
More than half (53%) of the co-infected patients were between the age groups 30 and 39 with 
almost a quarter of them (23%) in the 0-29 age group. This indicates that the burden of co-
infection with TB and HIV at both clinics were predominantly among the economically 
productive age group (i.e. the workforce). Even though the antenatal HIV prevalence report 
(2006) which serves as a reliable indicator of the progression of HIV/AIDS in SA showed a 
decrease in prevalence rates among the younger age group (30-39), the finding above is contrary 
to that report since majority of the co-infected patients during this phase belonged to the younger 
age group (30-39).  
 
Table 6.2.2: Correlation between patient weight and CD4 count 
Weight(in kg) Frequency Percentage (%) 
40-49 20 23 
50-59   32 37 
60-69  28 32 
70-79 4 4.6 
80-89 3 3.4 
Total  86 100 
CD4 count Frequency Percentage (%) 
0-49 17 19.3 
50-99   15 17.0 
100-149 28 31.8 
150-199 17 19.3 
200-249 6 6.8 
250-299 4 4.5 
300-349 1 1.1 
350-399 1 1.1 
Total  88 100 
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The weight of patients with immunocompromised conditions such as HIV is a determining factor 
in the initiation of their ARV treatment. The findings from this phase of the study showed that 
more than one-third (37%) of the patients who received the intervention had their recorded 
weights between 50-59kg, followed closely (32%) by patients having weights between 60-69kg 
and a few (3.4%) with a recorded weight between 80-89kg. A study showed a link between 
people with HIV and the negative effect of obesity on immunity. It was found that obese patients 
with HIV treated with ARVs gained fewer CD4 counts compared with their non-obese 
counterparts. Interestingly, this link was consistent with lower weights. In the absence of ARVs 
patients HIV disease progression was faster and fatal (Prasad R, 2007; Goodman A, 2009).  
 
Lower weights have been associated with poor patient response to their treatment and possibly a 
correlation could be established between a low weight and a low CD4 count (Goodman A, 
2009). The CD4 count is an indication of how patients with HIV are coping with their condition. 
Literature states that TB treatment can only be initiated in an HIV-positive patient when the CD4 
count is less than 200 (chapter 2, section 2.8) but in this study, almost one-third (31.8%) of the 
patients had their CD4 count between 100 and 149. If the CD4 count is an indication of how 
patients are coping with HIV, then it can be safely speculated that when their weight is low they 
are not coping well with the disease.  
 
A low CD4 count in co-infected patients with TB and HIV may be as a result of patients not 
starting ARVs on time thus these patients come to the clinic when they are very ill and are then 
fast-tracked.  Most of the patients were unemployed and had their CD4 count below 200, which 
qualified them for a disability grant. However, this may adversely affect patient adherence to 
treatment because they may be tempted to keep their CD4 count low so as to continue collecting 
the grant (Rowe et al, 2005; Bond V et al, 2009).  
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Table 6.2.3: Demographic profile of intervention patients  
 
 
 
 
 
 
 
 
According to the data above, patients are predominantly female black South Africans (78%) 
which is contrary to the Delft and Elsies River community demographic profile provided in 
section 3.1.2 and 3.1.3 (chapter 3), the reason for this could be that Delft as a community is 
divided into Delft and Delft South. More than half (53.8%; 50) of the patients surveyed in this 
study were females, again showing that generally the burden of these conditions are seen more in 
females than males (HSRC, 2005).  
 
Table 6.2.4: Patient diagnosis by their HCP 
Diagnosis Frequency Percentage 
Doctor 4 4.4 
Nurse 86 95.6 
Total 90 100 
 
 
Diagnosis of patient is nurse-based at a primary healthcare level, as most patients received 
treatment from nurses with medically trained doctors having less direct contact (Kagee A, 2004). 
Since nurses are predominantly responsible for the diagnosis and treatment at the primary care 
level, the involvement of doctors is minimal.  
 
Almost all (95.6%; 86) of the patients were diagnosed by nurses with either having TB, HIV or 
both conditions . In contrast, only 4 patients were diagnosed  by doctors as having both 
conditions. A possible explanation based on my observations could be the fact that the doctor 
only saw patients  twice a week (Tuesdays and Thursdays) whilst the clinic nurse who was 
present everyday, was the primary service provider involved in detecting, screening and 
diagnosing high risk patients. In this study, the workload on the clinic nurse is evident following 
the diagnosis of  86 co-infected patients. A trained pharmacist would be needed in such a setting 
Race Frequency Percentage (%) 
Black  71 78 
Coloured  20 22 
Total 91 100 
Gender Frequency Percentage (%) 
Female 50 53.8 
Male 43 46.2 
Total 93 100 
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to alleviate the workload on lack of the clinic nurse, where the medicine-related risks, including 
to TB/HIV adherence to treatment could be addressed.  
 
Table 6.2.5: Type of TB treatment case 
Case type Frequency Percentage (%) 
New 67 75.3 
Retreatment 22 24.7 
Total 89 100 
Type of pulmonary TB Frequency Percentage (%) 
N 67 75.3 
RAC 1 1.1 
RC 6 6.7 
RI 1 1.1 
RO 14 15.7 
Total  89 100 
 
 
More than 85% of people with TB in South-Africa have TB of the lungs known widely as 
pulmonary TB (Department of Health, 2006). In this study, majority (75.3%) of the co-infected 
patients were diagnosed as having new TB cases with a quarter (24.7%) receiving care for 
retreatment TB. Furthermore, 15.7% of patients were retreated after their previous completion 
(RO). These high retreatment cases clearly indicate that TB resurgence amidst the HIV pandemic 
is placing an enormous economic burden on the South African healthcare system. Pharmacists 
specializing in TB/HIV management are needed to undertake a clinical and patient-centered role 
alongside TB nurse practitioners. In providing such care pharmacists need to understand the 
patient’s medical and social barriers that influence treatment outcomes.  
 
Table 6.2.6: Patient adherence status 
Adherence Frequency Percentage (%) 
Bad  11 13.8 
Excellent  23 28.8 
Good  46 57.5 
Total  80 100 
 
Patient treatment adherence status was assessed from pill counts during the clinic visits. 
Adherence was assessed by using three keys which are outlined as follows; excellent adherence 
indicating that all pills were taken, good adherence indicating that 1-2 pills were leftover, and 
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bad adherence indicating that more than 2 pills leftover. The data presented here was largely 
supported by patient advocates who count pills and monitor patient adherence as part of their 
daily duties. Even though, more than half (57.5%) of the patients had achieved good adherence, 
just over a quarter of them (28.8%) adhered to their regimen excellently, while the rest (13.8%) 
of the patients seemed to adhere poorly to their treatment. The varying adherence status may be 
attributed to the poor rapport that exists between healthcare providers and patients with TB (Dick 
J et al, 2004).  
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Figure 6.2: Assessment of patient adherence status 
 
Even though the adherence status of patients in this study was mostly between good (45 patients) 
and excellent (24 patients), adherence is influenced by different factors. While there are 
numerous factors that contribute to poor adherence aside from the one stated above, in this study 
the most recognized factors are due to the patient’s socioeconomic status such as poor living 
conditions (overcrowding), lack of food due to unemployment, and lack of good sanitation. 
South Africans who are unemployed attend primary healthcare clinics that are often 
overcrowded, under-resourced and staffed by over-worked HCP’s (Kagee A, 2004). If basic 
needs such as good sanitation are not met, high risk patients become susceptible to infectious 
diseases. Consequently, they cannot maintain a sustainable income resulting in dependency on a 
disability grant. As social injustice prevails, infectious diseases that can be cured (TB) or 
controlled (HIV) will remain a challenge to the primary healthcare sector. Pharmacists who are 
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trained towards social responsiveness can engage with community partnerships to identify and 
address the injustice that impinge on healthcare. 
 
Table 6.2.7: Patient treatment outcomes and common side effects  
 
 
Almost two-thirds (64.4%) of the patients reported that they had experienced side-effects, more 
than one-quarter (26.4%) claimed to have experienced drug interactions, and few (9.5%) of the 
patients identified adverse effects (1.1%) resulting from drug therapies. A trained pharmacist 
could offer suggestions or devise approaches to manage drug interactions and side effects.  
 
Half of the patients indicated that they had experienced an increase in appetite (50%) as a side-
effect. This is a common side effect when patients take their medications regularly and can be 
taken as a positive sign of patient adherence. However, increased appetite may be a negative 
factor to patients who are unemployed or without disability grant because they may lack food. 
Other side effects recorded were decreased appetite (16.7%), nausea and vomiting (16.7%), 
diarrheoa (8.3%) and muscle weakness (8.3%).  
 
 
 
 
 
 
 
Treatment outcomes Frequency Percentage (%) 
Adverse effect 1 1.1 
Drug interaction 23 26.4 
Side effects 56 64.4 
Other  7 8.5 
Total  87 100 
Side effects Frequency Percentage (%) 
Decreased appetite 2 16.7 
Diarrhoea  1 8.3 
Increased appetite 6 50 
Muscle weakness  1 8.3 
Nausea and vomiting 2 16.7 
Total  12 100 
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Table 6.2.8: Patient drug interaction  
Drug Interaction Frequency Percentage 
(%) 
Rifampicin + Efavirenz 19 82.6 
Rifampicin + Nevirepine 4 17.4 
Total 23 100 
 
Rifampicin is a potent enzyme inducer of the liver enzyme P450 cytochrome. Rifabutin is a 
weaker enzyme inducer than rifampicin but unfortunately this drug is not available to the South 
African state sector e.g. clinics (Dawood H, 2006). The ART regimen has been modified to make 
it compatible with the standard, rifampicin-based TB treatment. The South African guidelines 
does not recommend increasing the dose of efavirenz when given together with rifampicin 
because of the risk of toxicity. Nevirapine is however well tolerated when co-administered with 
rifampicin. In this study, more than three-quarters (82.6%) of the patients received both 
rifampicin and efavirenz  thus they were at risk for toxicity especially in women since efavirenz 
has been shown to be teratogenic (WHO ART guidelines meeting review, 2009). 
 
Table 6.2.9: Number of other drugs taken by patients 
Number of other tablets Frequency Percentage 
Three 35 41.7 
Four 45 53.6 
Five 4 4.8 
Total  84 100 
 
 
More than half (53.6%) of the patients were taking four other tablets concurrently with their anti-
TB drugs. This finding may adversely affect patient adherence due to pill burden. However, 
patients taking Rifafour® may be an exception because this drug is a fixed-dose combination. 
More than one-third of the patients (41.7%) were taking three other drugs and a small percentage 
(4.8%) was taking five other drugs.   
 
6.3. Post intervention phase results (n=48) 
 
The aim of this study was to assess receptivity and effect of intervention on patient therapy. 
Data was collected using questionnaires (Appendix M and N) from 48 patients that had 
previously received the intervention during the pre-and intervention phases. The post-
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intervention questionnaires were originally designed in English language (Appendix M) and they 
were translated into isiXhosa (Appendix N) for those patients recruited from Delft South ARV 
clinic. A patient advocate (PA) working at this clinic assisted with data collection. The 
questionnaires administered to patients attending Elsies River were provided in the English 
language. 
 
In view of time and language constraints that were encountered during the pre-intervention 
phase, most of the questions in this phase were dichotomous (Yes or No). According to the 
research design (chapter 3, section 3.7.2), patients were distributed into four groups. However, it 
must be noted that the distribution of patients was uneven across the group. The reason for this 
was due to the fact that the researcher conducted the patient interviews within the personal 
workspace of the adherence counsellor and only gathered data after counselling was complete.   
Most of the patients were grouped as experimental 2 patients (see table 6.3.5) and received both 
the intervention and post-intervention. Data obtained was input into Epi Info (2003), analyzed 
and the results are outlined below. 
 
It must be noted that only 48 of the 98 patients recruited during the intervention phase was 
available for the post-intervention phase. The rest of the patients were lost to follow-up care.  
 
Table 6.3.1: Patients initial perception(s) of clinic pharmacist 
 
Only give medications to patients  Frequency Percentage (%) 
No  11 26.2 
Yes 31 73.8 
No interaction with patient  Frequency Percentage (%) 
No  18 41.9 
Yes 25 58.1 
All of the above  Frequency Percentage (%) 
No  12 28.6 
Yes 30 71.4 
None of the above  Frequency Percentage (%) 
No  24 55.8 
Yes 19 44.2 
Other perceptions Frequency Percentage (%) 
No  23 53.5 
Yes 20 46.5 
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In this study, almost three-quarters of the patients (73.8%) believed that pharmacist’s role 
focused primarily on dispensing of TB medications. This high response rate was further retained 
in a clarifying question that pharmacists are primarily involved in mechanical dispensing when 
more than half (58.1%) of the patients claimed to have had no interaction with the pharmacist. 
The patients’ initial perception is due to their minimal contact and interactions with the clinic 
pharmacist who is located in the clinic pharmacy. Even though undergraduate training 
programmes underpin the importance of patient-centered care, this role seems non-existent 
among public sector healthcare facilities in the Western Cape.  
 
As seen, the patients single most favoured perceived role for pharmacists was that they only gave 
medications (73.8%), and more than half (58.1%) of them perceived a poor level of patient-
pharmacist interaction.  
 
A study in Tanzania (2000) highlighted the role of the pharmacist in TB/HIV management. Their 
roles were primarily drug-related and included amongst others counselling of patients on 
adherence and their side effects, dispensing, ordering both isoniazid and pyridoxine supply.  This 
meant that pharmacists were primarily used as an information resource about procurement and 
stock of medicines thus, leaving a large proportion of the pharmacist’s pharmaceutical 
knowledge and skill untapped for use in patient-centered care. The perceptions of patients 
towards pharmacists at these clinics are primarily drug-related where there is no direct 
interaction. The movement towards the patient care approach has occurred to varying degrees in 
countries such as the UK and the USA where the role of the pharmacist has evolved from that of 
a compounder and supplier of pharmaceutical products towards that of a provider of services and 
information and ultimately to that of a provider of patient centered care (Williams K, 2006). 
 
One of the primary assessments of the intervention was to determine the potential clinic-based 
role of the pharmacist. I outline key findings that were obtained from this phase of the study.  
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Table 6.3.2: Key interventions by researcher on patient’s treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Identified new symptoms  Frequency Percentage (%) 
No 1 2.3 
Yes 42 97.7 
Identified side-effects Frequency Percentage (%) 
No 4 9.3 
Yes 39 90.7 
Referred patient to ARV doctor  Frequency Percentage (%) 
No 1 2.3 
Yes 42 97.7 
Suggested additional medication 
for side-effects  
Frequency Percentage (%) 
No  16 37.2 
Yes 27 62.8 
Informed patient about grant  Frequency Percentage (%) 
No  0 0 
Yes 43 100 
Advised on treatment  Frequency Percentage (%) 
No  1 2.3 
Yes 42 97.7 
Encouraged positive thinking and 
attitude  
Frequency Percentage (%) 
No  2 4.7 
Yes 41 95.3 
Other  Frequency Percentage 
No  0 0 
Yes 42 100 
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The researcher’s key interventions included identifying new symptoms, identifying side-effects, 
referring patients to ARV doctor, suggesting additional medication(s) for side effects, informing 
patients about grant, advising on treatment and encouraging positive thinking and attitude. 
Overall the patients’ responses were largely positive. Almost all (97.7%) of the patients surveyed 
responded positively as a result of  the researcher identifying new symptoms, referring them to 
the ARV doctor (97.7%) and advising on their treatment (97.7%). Other key interventions 
included encouraging patients on positive thinking and attitude (95.3%), identifying their side-
effects (90.7%) and suggesting additional medication to relieve unbearable side-effects (63.8%) 
accordingly. All the patients (100%) indicated that they were informed about the disability grant 
and the criteria for qualification.  
 
Since primary healthcare focuses on a collaborative multi-disciplinary team approach, patient 
views on this crucial aspect in service delivery were also explored.  
 
Table 6.3.3: Patients views on pharmacist working together with other HCP’s 
 
Doctor and pharmacist Frequency Percentage (%) 
No  0 0 
Yes 43 100 
Clinic nurse and pharmacist Frequency Percentage (%) 
No  0 0 
Yes 43 100 
Adherence counselor and 
pharmacist 
Frequency Percentage (%) 
No  0 0 
Yes 43 100 
Patient advocate and pharmacist Frequency Percentage (%) 
No  0 0 
Yes 43 100 
Other HCP and pharmacist Frequency Percentage (%) 
No  1 2.3 
Yes 42 97.7 
 
All the patients surveyed (100%) responded positively for the integration of services.  They all 
supported a multi-disciplinary team care approach to their treatment and it was interesting to note 
that these patients felt that potentially pharmacists could work alongside clinic nurses. As 
mentioned earlier, diagnosis of patients at both clinics was highly nurse-based but a nurse-led 
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clinic could imply a strong degree of independence. However if other healthcare professionals 
oppose it, then it is doomed for failure (Hatchett R, 2008). In addition, the sharing of knowledge 
and experience is a part of all nurses’ professional development thus a multi-disciplinary care 
team involving pharmacists would be vital in optimizing care provision. 
 
Table 6.3.4: Patients responses after exposure to the intervention 
 
Like to be attended to by the pharmacist Frequency Percentage 
No  1 2.5 
Yes 39 97.5 
Has patient perception changed?  Frequency Percentage 
No  1 2.3 
Yes 42 97.7 
 
 
The post-intervention data clearly shows that patient’s initial perceptions towards pharmacists 
had tremendously changed. Almost all (97.5 %;39) of the 48 patients surveyed at this phase 
wanted to be attended to by the pharmacist, giving a positive indication that pharmacist at these 
clinics were now being viewed positively as result of the intervention (trained researcher using a 
specially designed clinic record card).   
 
Furthermore, almost all (97.7%) of the patients surveyed, had changed their initial perception(s) 
towards the pharmacist. In conclusion, findings from the post-intervention patient study clearly 
underpin that a potential clinic-based role for the pharmacist is imminent.  
 
Summary of results according to research design 
According to the research design used in this study (Solomon-four group research design), the 
effect of the intervention was assessed by comparing experimental group 1 with control group 1 
and experimental group 2 with control group 2 (chapter 3, section 3.7.2).  It must be noted that a 
patient could only be grouped once i.e. a patient can be categorized only under one group. The 
total number of positive (“Yes”) responses obtained from the researcher’s key interventions was 
equal to total outlined on table 6.3.2.  
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Table 6.3.5: Comparison between experimental and control groups to assess the receptivity 
of the intervention among patients. 
Type of key interventions Experimental 1 Control 1 Experimental 2  Control 2  
Identified new 
symptoms(n=42) 
7 3 31 1 
Identified side effects(n=39) 6 3 29 1 
Referred patient to ARV 
doctor(n=42) 
6 3 32 1 
Suggested additional 
medications for side- 
effects(n=27) 
6 3 15 3 
Informed patient about 
grant(n=43) 
7 3 28 5 
Advised on treatment(n=42) 7 3 32 0 
Encouraged positive 
thinking and attitude(n=41) 
7 3 31 0 
Other interventions(n=42) 7 3 32 0 
Has patient perception(s) 
changed?(n=42) 
7 3 32 0 
 
Findings from above clearly indicates that experimental group 2 patients who received the 
intervention and post-intervention formed two-thirds (66.7%) of the study. The effect of the 
intervention was found to be significant when a comparison was made between experimental 
group 1 (received pre-intervention, intervention and post-intervention) and control group 1 
(received only the pre- and post-interventions). Seven out of the nineteen patients who received 
the pre-intervention gave positive responses to the following; researcher identified new 
symptoms, informed patient about grant, advised on treatment, encouraged positive thinking and 
attitude, other interventions and changed their initial perception towards the pharmacist. In 
contrast, only three out of nineteen control patients gave positive responses to all the researcher’s 
key interventions which resulted in a change from their initial perception. The difference in 
percentage could be attributed to the effect of the intervention since patients from control group 
1 did not receive it.  
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Due to the uneven distribution of patients a comparison could not be made between experimental 
groups 2 (received intervention and post-intervention) and control group 2 (received only the 
post-intervention). However, experimental group 1 can be compared with control group 2 
because the latter only received the post-intervention. When these two groups are compared, it is 
clear that the positive responses are due to the effect of the intervention. This conclusion is 
drawn because the ratio of experimental group 1 patients who changed their initial perceptions to 
control group two patients is an enormous 7:0.  
 
Furthermore, control group 1 (received pre- and post-intervention) can be compared with control 
group 2 (received only post-intervention). When these two groups are compared, it is clear that 
the pre-intervention succeeded in sensitizing patients, thus the number of positive responses 
recorded. In conclusion, the research design used in this study was appropriate in ascertaining the 
perceived effect of the intervention across three groups.  
 
Statistically, the Solomon four-group design demands a large number of patients thus its major 
drawback is that each of the four groups requires at least 30 patients. It’s evident from table 6.3.5 
that statistical analysis of the data cannot be applied (Yount R, 2006).  
 
Phase II 
6.4. The aim of the study was to assess final year pharmacy students’ current TB/HIV knowledge 
and assessed scores between students who had received an introductory clinic-based session 
(experimental group) with those who received the usual classroom based teaching (control 
group). The researcher designed an assessment (Appendix O) which served as the sole method of 
data collection for student groups. The assessment was divided into two parts with the first 
containing 19 questions and used to collect mainly quantitative data whilst the second part was in 
the form of a questionnaire and was used to collect mainly qualitative data. The maximum score 
for the assessment was 42.5 (100%) and the pass mark was set at 50% (21.25). The control 
students had one hour to complete the assessment whilst the experimental students completed the 
assessment after receiving the introductory clinic-based training from the researcher (chapter 5).  
The findings from the student’s assessment are provided below.  
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Section three: UWC final year pharmacy student’s results  
Table 6.4:  Responses between control (n=37) and experimental (n=7) students 
 
 Control Experimental 
Quantitative results   
Total number of students that 
wrote 
n = 37 n = 7 
Number of student that passed 15 7 
Number of students that failed 22 0 
Highest score 37.5 34.5 
Lowest score 17 29.5 
% passed 40.5 100 
% failed 59.5 0 
Range of marks  Frequency Frequency 
< 10 0 0 
10-25 8 0 
26-45 29 7 
Students knowledge of 1st line ARV 
regimen and dosages( numbers refer 
to marks) 
Frequency and Percentage 
(%) 
Frequency and Percentage 
(%) 
0-0.9 7 (18.9) 0 
1-1.9 21(56.8) 0 
2-2.9 8 (21.6) 3(42.9) 
3-4 1(2.7) 4(57.1) 
 
 
 
Case-study (C) and (D)  
C. Students knowledge of potential 
drug intervention between anti-TB 
and ARV’s( numbers refer to marks) 
  
0-0.9 28(75.7) 5(71.4) 
1-1.9 9(24.3) 2(28.6) 
2-3 0 0 
D. Students knowledge of the 
importance of Bactrim® and 
Vitamin B complex (numbers refer 
to marks) 
  
<0.5 1(2.70) 0 
0.5-0.9 8(21.6) 0 
1-1.5 28(75.7) 7(100) 
Students views on expanded role 
for pharmacists?  
  
No  0 0 
Yes  36(100) 7(100) 
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Students’ previous TB/HIV clinic 
training? 
  
No  29(80.6) 7(100) 
Yes  7(19.4) 0 
Support for 4th year clinic- based 
TB/HIV exposure? 
  
No  1(2.86) 0 
Yes  34(97.14) 7(100) 
 
Qualitative results 
 
  
Students opinions on expanded role 
for pharmacists 
…..roles that are drug- 
related (n=3) 
 
…to guide patients through 
their medication and 
condition. 
 
….to minimize drug 
interactions and side 
effects. 
 
… Patients value 
pharmacist’s opinions since 
they are custodians of 
medicines. 
 
 
…roles relating to 
counselling and adherence 
(n=13) 
 
…pharmacists should be 
involved in patient 
counselling and education. 
 
…pharmacists should be 
involved in patient care to 
aid in compliance and 
adherence of patients.  
 
…roles that are clinical 
(n=6) 
 
…pharmacists should be 
well informed to undertake 
 
(n=3) 
 
…pharmacists need more 
information on drug 
interactions and side 
effects. 
  
…pharmacists are drug 
agents thus they know drugs 
more than any other HCP’s. 
 
 …pharmacists can also 
help patients with potential 
side effects  
 
 
 
 
(n=2) 
 
…pharmacists should 
explain side effects and 
counsel patients.  
 
…pharmacists can directly 
interact with the patients 
and help them understand 
their drug therapy. 
 
 
(n=1) 
 
 …pharmacists should 
supply information on 
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patient centered care and 
lifestyle modification. 
 
…pharmacists should be 
allowed to test TB/HIV 
patients since they have 
more knowledge. 
 
 
…roles that are clinical 
and relates to counselling 
(n=2) 
 
…Pharmacy has become 
more clinical and 
pharmacists can give advice 
to other HCP’s on 
treatment of patients. 
 
health, lifestyle 
modifications and all 
information pertaining to 
drugs. 
 
 
 
 
 
 
 
 
Summary of students feedback on 
clinic training to supplement 4th 
year class lectures on TB/HIV 
management 
TB/HIV counselling 
sessions 
 
VCT training 
TB/HIV testing 
techniques 
 
Dealing with actual 
case-studies 
 
Role-playing 
 
Attending HIV pre- and 
post-counselling 
sessions 
 
Exposure to clinic 
TB/HIV management, 
 
TB/HIV course 
 
Adherence counselling, 
Support groups/clubs 
 
Mandatory involvement 
at HIV clinics 
Practical counselling 
sessions (OSCE’s) 
 
Recognition of side 
effects due to drugs 
 
Practical hands-on 
approach 
 
Visits to TB/HIV clinic 
to experience   
 
PALSA Plus training 
 
Protocols used in 
TB/HIV clinics 
 
Treatment criteria used 
in clinic 
 
TB/HIV counselling 
processes 
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6.4.1. Results 
It must be noted that assessment scores obtained from the control and experimental students 
groups could not be compared due to the difference in sample size. However, the scores were 
assessed to find common themes between the two groups and these were recorded in table 6.4. 
Out of the 37 control students, 15 students passed whilst 22 students failed. The highest score 
recorded was 37.5 (88%) and the lowest score was 17 (40%). Less than half (40.5%) of the 
control students passed the assessment while in contrast, an overwhelming 59.5% of them failed.  
 
All seven (100%) of the experimental students group passed the assessment and the scores 
ranged between 26 and 45. More than three-quarters (78.4 %; 29) of the control students passed 
with marks between 26 and 45, and less than a quarter (21.6%; 8) of these students had marks 
between 10 and 25.  
 
0
5
10
15
20
25
0-0.9 1-1.9 2-2.9  3-4
Knowlegde of first-line ARV regimen
Control
Experimental
 
Figure 6.3: Students knowledge of first line ARV regimen 
 
More than half (56.8%; 21) of the control students scored between 1 and 1.9, eight (21.6%) 
scored between 2 and 2.9, seven (18.9%) between 0 and 0.9 and only one (2.7%) student scored 
between 3 and 4. Almost half (42.9%) of the experimental students scored between 2 and 2.9, 
and four (57.1%) scored between 3 and 4. This means that the experimental groups were able to 
apply theoretical concepts to practice-based scenarios. This result is also evident from their 
knowledge of potential drug-drug interactions and the importance of Bactrim® and vitamin B. 
Complex among patients in TB/HIV management. 
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Figure 6.4: Student’s knowledge of potential drug interactions 
Students’ knowledge of potential drug interaction between anti-TB drugs and ARV’s showed 28 
(75.7%) control students scoring between 0 and 0.9 and nine students scoring between 1 and 1.9. 
Five experimental students scored between 0 and 0.9 and two students between 1 and 1.9.  
 
 
Figure 6.5: Students knowledge of Bactrim® and Vitamin B complex importance  
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All (100%) seven of the experimental students scored between 1 and 1.5 and while three-quarters 
(75.7%; 28) of the control students scored between 1 and 1.5. One control student and eight 
control students scored less than 0.5 and between 0.5 and 0.9 respectively.  
 
Common themes amongst control and experimental students 
 
It was interesting to note that all (100%) students from both the control and experimental groups 
supported an expanded role for the pharmacist. Three out of the 37 control students had opinions 
that were drug-related (three for experimental), 13 had opinions that related to counselling and 
adherence (two for experimental), six had clinical opinions (one for experimental), and two 
control students had opinions that related to counselling and clinical involvement. Five control 
students and one experimental student did not state their opinions. Seven control students gave 
opinions that were not pharmacy related. This question provided positive responses that were 
both quantitatively and qualitatively relevant to this study.  
 
For example, 32 out of the 37 control students (86.5%) and six out of the seven experimental 
students (85.7%) stated their opinions. These two percentages are virtually the same 
quantitatively (less than 1.0% difference) and qualitatively, the student’s opinions across the 
groups were also very similar even though only seven of them received the training. 
Furthermore, student’s opinions were qualitatively relevant to this study because the responses 
obtained showed that both trained and untrained students supported an expanded role for 
pharmacists that was not only drug-related but was also clinical, and involved direct patient 
interaction (counselling).  
 
All (100%) the experimental students and more than three-quarters (80.6%) of the control 
students had no previous TB/HIV training. Less than a quarter (19.4 %; 7) of the control students 
answered “Yes” to that question and according to these seven students TB/HIV training included 
exposure to an ARV pharmacist during SLIP rotation, how to live with HIV-positive people, 
assisting the ARV pharmacist with dispensing and counselling, and knowledge of ARV generics 
such as Aluvia®. Out of these seven students only two actually underwent a proper training, one 
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at Dr. Nkanyetsi Hospital for two months and the other with the HIV South African clinician’s 
society (2007) conducted by Dr. Lin Webb.  
 
All seven (100%) of the experimental students and almost all (97.14%) of the control students 
supported a clinic-based TB/HIV exposure and only a few (2.86%) of them answered “No” to 
that question. Students had varying, and overlapping views on clinic training to supplement their 
4th year class lectures on TB and HIV management. This question was open-ended question to 
allow students express and suggest their views freely.  
 
As stated above, students from both control and experimental groups felt that TB and HIV 
counselling sessions were important which corresponds with the SAPC’s role for pharmacists. 
The students also shared overlapping views such as dealing with actual case studies (control) 
which corresponds with a practical hands-on approach (experimental), role-playing (control) 
corresponds with practical counselling sessions (experimental). It is obvious that the students 
were of the general opinion that the clinical management of TB and HIV requires clinical 
exposure and direct involvement from the pharmacist. 
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6.4.2. Students feedback session on PALSA Plus training received 
 
As mentioned earlier in the research methodology (chapter 3, section 3.2.1), seven students were 
recruited as experimental students. The PALSA Plus training feedback session was conducted on 
the same day after the training (June 9, 2009). The students gave their feedback immediately 
after writing the assessment and each feedback was anonymous.  
 
Key for feedback 
S: represents the students 
S1: represents student one 
S2: represents student two and this consecutive order will be followed for all the subsequent 
students with whom I trained.  
 
 
 Practical approach to learning 
 
Some students felt that the PALSA Plus training was a very practical approach to dealing with 
the clinical management of TB and HIV. They felt that it was the closest resemblance to what 
really happens in a clinic that provides integrated TB/HIV care to co-infected patients: 
 
S1:  “the training provided better practical view on drug use. I felt good case study examples 
were used and the researcher stayed much on track with issues to discuss on outline and cleared 
all small issues like why Bactrim® and Vitamins B6 and B complex were used. Practical issues 
like patients refusing medicines were also dealt with”. 
 
S3:  “I learnt new interesting facts from the training...... It showed me the practical and technical 
side of TB/HIV treatment. I think it is very important for students to know the practical side and 
to learn how to apply the theory in real life.  
……It (PALSA Plus training) offered me the opportunity to ask questions on TB/HIV treatment in 
more detail. It showed me how to use my knowledge or theory in the practical field”. 
 
S7: “I found the training session very helpful in the sense that I was able to put the theory learnt 
into perspective. It helped me assess how much I already knew and refreshed the aspects of 
TB/HIV treatment which I had forgotten or didn’t understand previously.  
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Educational approach to primary healthcare  
 
Some students felt that the PALSA Plus training was very educational and hands-on. They felt 
that it was a way to get better attuned to the realities of primary care level treatment and care: 
 
S2: “The training was very useful as it helps us get out of the classroom scenario and visualize 
what goes on in the primary healthcare level. I now have a better understanding of TB/HIV 
management.  
……It (PALSA Plus training) was also educative as I got to see the tools used for TB diagnosis 
and management in primary health care e.g. TB treatment wheel and TB screening tool. It was 
an eye- opening experience”. 
 
S4: “It (PALSA Plus training) was educational as some of the issues dealt with I did not know in 
detail ….or did not really think about…... It made me think about a lot of things that would be of 
concern to patients that I was unaware of”. 
 
S5: “I felt it was a very informative session as I applied my theory to practice.  
…..It will be extremely useful in a TB/HIV management setting”. 
 
S7: “I learnt about the TB treatment wheel as it was my first time of hearing and seeing it”. 
 
Support for integration into 4th year curriculum 
One student felt that the training was so important it had to be implemented into the current 4th 
year pharmacy curriculum:  
 
S5: “I suggest its (training) usefulness if all 4th year pharmacy students were to receive this 
training. The session was clear, concise and highlighted the important points of TB and HIV 
….. It brought a better or enhanced understanding of TB/HIV and protocols implemented in 
primary health care”. 
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Training was well presented 
One student felt the training was well presented in a manner they could relate to, and was not 
similar to what they were used to in class lectures:  
 
S6: “I think the training was well planned and it was more informative as it focused mostly on 
the practical approaches of the intervention. 
…..It was not over- loaded with information as the content was well presented and information 
presented was well managed. Most of the content was kept straight and simple to the point”.  
 
Following the student’s feedback provided above, it can be safely concluded that the 
introductory clinic-based session was successful. As evident from student’s performance and 
feedback, rigorous studies are needed to plan, implement and evaluate a clinic-based training 
programme for pharmacy students at primary care clinics. 
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CHAPTER 7: DISUSSION  
The aims of this study were to assess the current practice patterns at TB/HIV primary healthcare 
clinics in the Western Cape and the need for a clinic-based TB/HIV training among final year 
pharmacy students at UWC.   
This discussion focuses on the implications of the findings obtained from patients and HCP’s 
(Phase I study) and final year pharmacy students (Phase II study). The key themes emanating 
from the Phase I study are the potential involvement of trained pharmacists in a clinic-based 
TB/HIV programme, the provision of patient-centered care, impact of the clinic-based 
intervention and inter-professional teaching and learning opportunities. For the Phase II study, 
the potential for clinic-based TB/HIV training for pharmacy students is highlighted. Finally, the 
use of mixed methods in this exploratory study is outlined.  
In countries such as the USA and UK, the pharmacy profession has evolved beyond mechanical 
dispensing (Wiedenmayer VK, 2007). However, pharmacy in South Africa’s public healthcare 
sector is confronted by an increasing demand on the primary healthcare services which is 
compounded by chronic diseases and exacerbated by the HIV/AIDS epidemic (Assal, 1999; 
Gilbert, 2004a; Yach & Hawkes, 2004). Primary healthcare has the potential to improve the 
quality of care given to patients with chronic illnesses provided that HCP’s are trained for their 
roles (Becker MH et al, 1974; Wasson JH et al, 1984; Starfield B, 1992; Hjortdahl P, and 
Laerum E, 1992; Pearson P, and Jones K, 1994).  
7.1. Current TB/HIV clinic-based practice patterns: Does it allow for pharmacist 
involvement? 
 It is inevitable that the patients viewed pharmacists as peripheral healthcare service providers as 
they lacked direct involvement with care provision (Rennie TW, 2009). Even though pharmacists 
may have the knowledge on medicine use, the current organizational structures in public sector 
primary healthcare facilities preclude them from engaging in clinic-based interactions. However, 
findings from this study indicate that integrating a trained pharmacist in a patient-centered 
approach to TB and HIV management remains a possibility.   
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7.2. A patient-centered approach to TB and HIV management 
The Doncaster model suggests that pharmacists should work outside the dispensary where the 
patients’ medical notes, doctors and nurses are present (Andalo D, 2002). In this study, the 
researcher worked directly with co-infected patients thereby establishing a patient-researcher 
relationship, which was positively received as a part of service delivery. Following from this 
patient-centered approach, it is evident that medicine related needs or risks could be identified. In 
addition, complex social, behavioural and cultural issues that impact on treatment adherence can 
be recognized and addressed collectively within the existing health system. A ‘covenantal’ 
relationship based on morals and values between the patient and a trained pharmacist is therefore 
imminent (Williams KE, 2007). A patient-provider relationship which builds on patient 
understanding and one that promotes self-responsibility for healthcare should not be under-
estimated (Report on the integration of TB an HIV services in Site B Khayelitsha, 2005). 
Adherence is associated with a strong doctor and patient relationship (Ciechanowski PS 
et al, 2001; Catz SL et al, 2001; Roberts KJ, 2002). Therefore, pharmacist’s active involvement 
results in establishing strong relationships with patients that will influence their adherence 
outcomes.   
7.3. Impact of the clinic-based TB/HIV intervention 
While this study revealed the positive impact and influence that HCPs especially the adherence 
counsellor and clinic nurse have on patient treatment, several gaps were identified in drug 
therapy in current practice patterns. These included the identification of side effects, 
pharmaceutical implication(s) of crushing TB/HIV tablets and referral of patients to the TB/ARV 
doctor. 
The key interventions which ranged from identifying new symptoms, identifying side-effects, 
suggesting additional medication for side-effects, informing patients about grants, encouraging 
positive thinking and attitude (see table 6.3.2) may be attributed to the researchers’ clinic-based 
PALSA Plus training, a thorough understanding of routine clinic procedures and designing and 
using the clinic record card. This clearly illustrates that pharmacotherapeutic concepts were 
being applied in ‘real practice’. Prior to implementation of the intervention, patients did not view 
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pharmacists as important providers of care. However, data from the post-intervention showed 
that patient’s perceptions changed following their direct engagement with the researcher.  
7.4. Inter-professional teaching and learning opportunities 
Even though HIV is a chronic illness that can be well managed by the patient and attending 
HCPs, its management is complicated with TB-co-infection. Successful chronic disease 
management usually involves a coordinated multidisciplinary care team that relies on effective 
interventions. Successful teams often include nurses and pharmacists with clinical and 
behavourial skills that ensure the critical elements of care are competently performed (Austin BH 
et al, 1996; Davis C et al, 1997; Calkins E et al, 1998; Wagner EH et al, 1998). When 
pharmacists work within such a team, they will be viewed as important care providers to patients 
and HCPs. This point was proven when patients fully supported (100%) pharmacists working 
with other HCP’s such as doctor, clinic nurse, adherence counsellor and patient advocate.  
 
7.5. Integrating services for co-infected TB/HIV patients  
 
The treatment of dually infected patients facilitates the early screening and diagnosis of TB and 
HIV. Separating services in co-infected patient’s results in care that is often fragmented (Tsiouris 
SJ et al, 2007). It is therefore essential, in areas of high HIV prevalence and TB burden (such as 
Delft South ARV clinic and Elsies River TB clinic) that national TB and HIV programs at the 
primary care level provide integrated care for TB/HIV to improve cure rates (Treatment Action 
Campaign, 2001). In addition, patients attend one consultation rather than two, which reduces 
travelling costs and waiting times (Report on the integration of TB and HIV services in Site B 
Khayelitsha, 2005).   
 
7.6. Influence of socioeconomic and educational status on treatment adherence 
 
Patient adherence is essential to achieving treatment success rates in TB and HIV management 
(Kagee A, 2004). Various factors affect patient adherence in the South African primary 
healthcare system, some of which were encountered in this study. They include amongst others 
socioeconomic factors and the educational status of the community. Social and economic factors 
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often combine to yield poor adherence outcomes which are worsened by poor treatment 
outcomes such as side-effects, drug interactions and adverse effects. Simoni and colleagues 
(1995) found low levels of adherence to the correct number of pills, dosing schedules and special 
instructions in a sample of HIV-positive patients. In this study, even though more than half 
(57.5%) of the patients attained good adherence (see chapter 5) almost two-thirds (64.4%) 
claimed to have experienced side-effects. As reported earlier, lack of food adversely influences 
treatment outcomes (Rowe KA et al, 2005). In this study, increased appetite was the most 
common reported side-effect (Table 6.2.7), thereby posing a problem for communities who 
cannot afford additional meals. In contrast, studies carried out in developed countries revealed 
that the most frequently cited reason by patients stopping their medications was side-effects 
(Chesney MA et al, 2000; Ammassari A et al, 2001). In underserved communities, lack of food 
coupled with an increase in appetite would adversely affect treatment adherence levels. In studies 
identifying the variables associated with non-adherence, a higher level of adherence was 
associated with higher education, and higher knowledge of their treatment (Williams KE, and 
Bond MJ, 2002). A correlation was also established between patients employment status, 
education, alcohol consumption with adherence outcomes (Kagee A, 2004). Similarly, in this 
study a correlation was reported between the level of patient education and knowledge of their 
conditions (see section 6.1).  
 
In order to equip the graduates with the skills in the management of diseases that impose a health 
burden, it is crucial that clinic-based training forms part of the core curricula. In this exploratory 
study we attempted to assess the need for a clinic-based exposure for pharmacy students. There 
is a paucity of South African literature that explores the need for clinic-based TB/HIV training 
for pharmacy students. However, studies done in countries like the United States made notable 
references to the importance of involving pharmacy students in clinic-based activities such as 
immunization, whereby such training formed part of the core curricula (Bain TB, and Cullison 
MA, 2009).  Medical students at the University of Colombo, Sri Lanka favoured clinical 
exposure as a better form of  learning medicine than the traditional teacher oriented system as it 
provides a better understanding of their theoretical knowledge (Health Action International, 
2005; 7-8).  
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7.7. Need for TB/HIV clinic-based exposure for pharmacy students 
 
For the Phase II study, I discuss the students’ performance in the clinical scenarios and the 
potential for supplementing clinic-based TB/HIV training with classroom teaching at UWC.   
 
7.7.1. Student’s performance in clinical scenarios 
The assessment used in this study explored the final year students’ application of their theoretical 
knowledge in clinic-based routinely encountered practice type case scenarios. Even though 
students performed fairly in the case scenario (see Appendix O, b and c), they were unable to 
identify common drug interactions between ARVs and anti-TB drugs and the initiation of ART 
in patients co-infected with TB having a CD4 count below 50. This may be attributed to lack of 
supplementary clinic-based exposure where the learning process is translated into practice and 
becomes more meaningful and consolidated. A Malaysian study which aimed to assess basic 
knowledge of HIV/AIDS and ART amongst pharmacy students clearly indicated the need for 
comprehensive training to improve their knowledge (Syed AI et al, 2009). Overall, the 
shortcomings clearly underpin the need for supplementary clinic-based TB/HIV training for 
pharmacy students.  
 
At UWC, the service learning programme conducted at primary healthcare facilities is pivotal in 
engaging students in clinic-based learning. The SLIP rotations for final year pharmacy students 
should include exposure to TB/HIV clinics where inter-professional learning and teaching 
opportunities could be consolidated. Students could work alongside the clinic nurse, patient 
advocate and adherence counsellor where factors that affect treatment adherence and health 
outcomes can be fully contextualized. Through meaningful engagement with patients and clinic 
staff, this “hands-on” learning would enable students understand the local and contextual factors 
that affect adherence. This “social contract” would provide the platform for pharmacy students to 
accept responsibility for the outcomes of care (Berger BA, 2009).  
 
Student feedback on the introductory clinic-based TB/HIV session indicated that such training is 
largely lacking in undergraduate pharmacy programmes (Eybers I et al, 2009). Barriers such as 
lack of contact between pharmacy students and patients may be responsible for the student’s 
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poor clinical knowledge (Bheekie A et al, 2007). Clinic-based TB/HIV training for 
undergraduate pharmacy students should become institutionalized so that graduates are able to 
understand the local context in which primary healthcare is delivered and received.  
 
7.8. Effectiveness of mixed methods in this study 
 
The use of mixed methods in this exploratory study was successful in obtaining both quantitative 
and qualitative data. This approach allowed the researcher to obtain a comprehensive 
understanding of TB/HIV management in primary healthcare clinics. The study design provided 
additional perspectives and insights that were beyond the scope of using a single technique, as at 
some stage of the research the data was either relayed, integrated, or mixed (Cresswell JW et al, 
2004). For example, using a single technique such as using a questionnaire (quantitative) to 
collect data throughout the study would have limited the depth of the enquiry process in the 
clinic. The qualitative participatory approach allowed the researcher to obtain key practical 
insights on disease management and inter-professional learning opportunities to design and 
implement the intervention. The results from both phases of the study are not generalisable due 
to the small sample size. More rigorous studies are needed to explore the potential role of 
pharmacists in TB/HIV management.  
  
This study clearly demonstrated the establishment of a “covenantal relationship” between the 
trained researcher and the patients and healthcare providers where medicine-related risks were 
identified. Several fundamental barriers impede the public health system provision of patient-
centered care from pharmacists. Pharmacist interaction with patients, other healthcare practioners 
and knowledge integration are necessary for both clinical exposure and application of theoretical 
concepts.  
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Conclusions and recommendations 
 
 
This study clearly underpins the need for trained pharmacists in primary healthcare clinics that 
provide integrated care for patients co-infected with TB and HIV. A trained pharmacist can work 
alongside other healthcare professionals to optimize the provision of care and welfare of co-
infected patients. A clinic-based role would enable trained pharmacists to screen patients for TB 
symptoms, identify side-effects and refer patients to the ARV doctor for further management. A 
specially adapted TB clinic record card serves as a useful tool to engage pharmacists in clinic-
based pharmaceutical care.  
 
One issue that confronts pharmacy education is the lack of experiential learning at primary care 
facilities. Therefore, student’s assessment on TB and HIV should become more practical and 
focus on real-life case scenarios. The current SLIP programme should include exposure to TB 
and HIV clinics where students could engage directly with patients to establish a value-based 
relationship on medicine-related risks and accept responsibility for patient health outcomes. 
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